2019 International Congress » Parkinsonisms and Parkinson-Plus

Date: Tuesday, September 24, 2019

Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Meeting: 2019 International Congress

1:45pm-3:15pm: “Familial imprint” of Parkinson disease: the siblings’ cohort of PROPAG-AGEING

L. Baldelli, F. Provini, S. Schade, S. Jesús, P. Gómez-Garre, L. Sambati, S. Schreglmann, G. Calandra Buonaura, C. Halsband, M. Carrion, K. Bhatia, P. Mir, P. Cortelli, B. Mollenhauer, C. Trenkwalder, PPG. Propag-Ageing Consortium (Bologna, Italy)

1:45pm-3:15pm: [18F] FDG-PET findings associated with cognitive impairment if multiple system atrophy

KW. Park, NR. Choi, SY. Jo, SJ. Kim, YJ. Park, SJ. Chung, CS. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: [18F]THK-5351 PET Imaging in Progressive Supranuclear Palsy Concomitant with Cerebellar Ataxia in Early-stage: Clinicopathological Observations

Y. Saitoh, K. Komatsu, E. Imabayashi, A. Moriya, H. Matsuda, Y. Saito, Y. Takahashi (Tokyo, Japan)

1:45pm-3:15pm: 123I-FP-CIT SPECT imaging in early PD patients versus mid and late onset PD: Longitudinal data from the PPMI study

C. Koros, A. Simitsi, M. Stamelou, A. Prentakis, A. Bougea, I. Pachi, D. Papadimitriou, I. Beratis, N. Papagiannakis, E. Angelopoulou, S. Papageorgiou, X. Geronicola Trapali, L. Stefanis (Athens, Greece)

1:45pm-3:15pm: 131-MIBG is less promising in differentiating Parkinson’s disease from other parkinsonism for early onset patients

D. Xu, WJ. Zhu, H. Wang, L. Huo (Beijing, China)

1:45pm-3:15pm: A case of osmotic demyelination syndrome presenting parkinsonism affected by blood alcohol concentration change

M. Kondo, A. Unaki, T. Kimura (Tokyo, Japan)

1:45pm-3:15pm: A characterization of the ADL-level in daily life with Parkinson`s Disease based on objective measurements and subjective experiences.

T. Thomsen, T. Kjær, L. Jørgensen, A. Haahr, K. Winge (Roskilde, Denmark)

1:45pm-3:15pm: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of Alpha-Synuclein Aggregation

D. Stamler, M. Bradbury, C. Wong, E. Offman (Newark, CA, USA)

1:45pm-3:15pm: A flowchart algorithm for the neurologist to discuss and attend sexual issues in Parkinson’s disease

G. Bronner, S. Hassin-Baer, AD. Korczyn, T. Gurevich (Ramat-Gan, Israel)

1:45pm-3:15pm: A general impaired-rhythm system underpins oro-motor, manual, and gait rhythmic disturbances in Parkinson’s disease

F. Puyjarinet, V. Bégel, C. Gény, V. de Cock, V. Driss, M. Cuartero, S. Pinto, S. Dalla Bella (Montpellier, France)

1:45pm-3:15pm: A genome wide pleiotropic approach to identify the genetic architecture of multiple system atrophy and its interaction with Parkinson’s disease

A. Ashokkumar Sreelatha, A. Shadrin, C. Blauwendraat, O. Frei, T. Gasser, G. Wenning, A. Singleton, H. Houlden, S. Scholz, O. Andreassen, M. Sharma (Tübingen, Germany)

1:45pm-3:15pm: A Lewy body disease of widely confirmed Lewy bodies in the cerebral cortexes including the occipital lobe without pathological changes in the hippocampal CA2/3 region

M. Ryo, K. Hasegawa, I. Saitoh, S. Yagishita (Tokyo, Japan)

1:45pm-3:15pm: A possible case of prodromal DLB with prominent hallucinations, autonomic dysfunction, and REM behavior disorder but absence of cognitive impairment

K. Amodeo (Rochester, NY, USA)

1:45pm-3:15pm: A study of factors causing psychiatric abnomalities in patients with Parkinson’s disease

T. Syed, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes

F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, F. Agbo, R. Kleiman, D. Blum, B. Navia (Rome, Italy)

1:45pm-3:15pm: Aberrant structural connectivity of the executive network in Progressive Supranuclear Palsy

S. Prasad, A. Rajan, S. Mangalore, J. Saini, M. Ingalhalikar, P. Pal (Bangalore, India)

1:45pm-3:15pm: Abnormal Intracortical Facilitation in patients of Parkinson’s disease with REM Sleep Behavior Disorder

A. Bhattacharya, N. Kamble, R. Yadav, PK Pal

1:45pm-3:15pm: Abnormal metabolic brain network in multiple system atrophy and progressive supranuclear palsy: a replication on a new European cohort

T. Rus, E. Rebec, P. Tomše, A. Studen, M. Grmek, C. Tang, D. Eidelberg, M. Trošt (Ljubljana, Slovenia)

1:45pm-3:15pm: Abnormal respiratory rate and patterns in MSA

E. Driver-Dunckley, B. Goodman (Scottsdale, AZ, USA)

1:45pm-3:15pm: Accuracy of clinical diagnosis of atypical parkinsonism: comparison of consensus clinical criteria with MRI criteria

D. Gwendoline, G. David, D. Bertrand, L. Stephane, C. Florence (Paris, France)

1:45pm-3:15pm: Accuracy of preoperative microelectrode trajectory planning in patients treated with DBS – an ongoing study

S. Ibrulj, S. Delalić, MB. Benedičič, D. Georgijev, DF. Flisar, M. Trošt (Ljubljana, Slovenia)

1:45pm-3:15pm: Acute Onset Parkinsonism Secondary to West Nile Virus Encephalitis

M. Purbaugh, F. Ali, T. Diesing, A. Hellman (Omaha, NE, USA)

1:45pm-3:15pm: Acute parkinsonism following an obstructive hydrocephalus and a ventriculoperitoneal shunt revision: a case report

J. Majuri, HR. Maanpää, A. Kotkansalo, J. Korpela, J. Joutsa (Lahti, Finland)

1:45pm-3:15pm: African American patients with Parkinson’s disease: A hospital-based study compared to Caucasian patients

T. Xie, D. Lee, M. Padmanaban, H. Yu, W. Kang, J. Johnson, J. Alshaikh, C. Yuen, M. Burns, F. Qian, B. Chiu (Chicago, IL, USA)

1:45pm-3:15pm: Alpha-synuclein expression and cytokine profile in blood of patients with Lewy body dementias

T. Usenko, M. Nikolaev, A. Bezroukova, A. Emelyanov, E. Gracheva, I. Milukhina, Y. Belceva, N. Zalutskaya, A. Timofeeva, S. Pchelina (Gatchina, Russian Federation)

1:45pm-3:15pm: Alpha-synuclein seeding activity in blood samples from synucleinopathy patients

T. Yamasaki, E. Song (Lexington, KY, USA)

1:45pm-3:15pm: Ambroxol treatment of primary macrophages derived from patients with GBA-associated Parkinson’s disease

A. Kopytova, M. Nikolaev, K. Senkevich, G. Baydakova, I. Miliukhina, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)

1:45pm-3:15pm: Ambulatory monitoring of electrodermal activity (EDA) and Heart Rate Variability (HRV) for prediction of motor fluctuations in Parkinson’s Disease (PD)

D. Nene, P. Surathi, M. Mirian, W. Doo, M. Mckeown (Vancouver, BC, Canada)

1:45pm-3:15pm: Amimia in Parkinson’s Disease and its Relationship with Motor and Non-Motor Symptoms

T. Maycas-Cepeda, C. Feliz-Feliz, L. Gomez-Vicente, R. García-Cobos, P. Lopez-Ruiz, R. Arroyo, PJ. García- Ruiz (Pozuelo de Alarcon, Spain)

1:45pm-3:15pm: Amylin and insulin in Parkinson’s disease patients: a clinical and metabolic study

A. Sánchez-Gómez, M. Fernández, G. Alcarraz, R. Fernández, M. Ezquerra, A. Cámara, A. Novials, E. Muñoz, F. Valldeoriola, Y. Compta, MJ. Martí (Barcelona, Spain)

1:45pm-3:15pm: Amylin deposition in the brain of Parkinson’s disease patients

I. Martinez-Valbuena, R. Valenti-Azcarate, J. Sanchez, I. Marcilla Garcia, G. Marti Andres, MT. Tuñon-Alvarez, MR. Luquin Piudo (Pamplona, Spain)

1:45pm-3:15pm: Amylin single-nucleotide polymorphism and Parkinson’s disease

R. Valenti-Azcarate, I. Martinez-Valbuena, I. Marcilla Garcia, G. Marti, M. Carmona-Abellan, MT. Tuñon-Alvarez, MT. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: An atypical and interesting feature of Parkinson´s disease

B. Santos, M. Spitz (Rio de Janeiro, Brazil)

1:45pm-3:15pm: An outlook: Palliative care for patients with Parkinsonism syndrome

MI. Arain (Jamshoro, Pakistan)

1:45pm-3:15pm: Analysis of cortical oscillatory activities may identify a subgroup of Parkinson’s disease patients with suboptimal responses to deep brain stimulation of the subthalamic nucleus

M. Bočková, M. Lamoš, P. Klimeš, P. Jurák, J. Halámek, S. Goldemundová, M. Baláž, I. Rektor (Brno, Czech Republic)

1:45pm-3:15pm: Apigenin loaded Phospholipid based nanoemulsion in Therapeutics of Parkinson’s Disease Via Attenuation of Oxidative Stress and Upregulation of Dopamine.

M-R. Rahman, V-K. Kumar (Allahabad, India)

1:45pm-3:15pm: APOmorphine infusion and aMYLoid deposition in Parkinson’s disease (APOMYL): preliminary clinical and amyloid imaging data

D. van Wamelen, M. Politis, D. Aarsland, P. Odin, T. van Laar, T. Henriksen, B. Corcoran, G. Vivian, H. Wilson, M. Parry, A. Sauerbier, N. Mulholland, K. Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Applicability of modified definition of Vascular Parkinsonism in patients with Parkinsonism attending outpatient department: A tertiary care hospital-based study in south India

S. Jaiswal (Hyderabad, India)

1:45pm-3:15pm: Application of the Movement Disorders Society Criteria for diagnosis of Progressive Supranuclear Palsy

F. Ali, H. Botha, E. Ahlskog, J. Bower, A. Hassan, D. Dickson, J. Whitwell, K. Josephs (Rochester, MN, USA)

1:45pm-3:15pm: Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (AT-HOME PD): An Update on Recruitment

R. Schneider, L. Omberg, T. Myers, S. Anthwal, E. Kayson, C. Tarolli, M. Daeschler, E. Macklin, E. Dorsey, L. Mangravite, M. Schwarzschild, T. Simuni (Chicago, IL, USA)

1:45pm-3:15pm: Assessment of neuronal morphology to determine the differential susceptibility to Parkinson’s disease using MPTP in two genetically distinct mice strains

B. Bhaduri, I. Datta, R. Yadav, P. Alladi (Bangalore, India)

1:45pm-3:15pm: Assessment of occupationally exposed organic solvents and welding fumes induced DNA damage and SNPs (PARK13, LRRK2 and CAST gene) and risk of Parkinson’s disease

K. Kalimuthu, R. Ramachndran, A. Arulsamy, S. Savariar (Annamalainagar, India)

1:45pm-3:15pm: Association between hand functions, hand reaction time and balance in patients with idiopathic Parkinson’s disease

AC. Kalkan, T. Kahraman, BO. Ugut, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Association between quality of life and physical functions in patients with idiopathic Parkinson’s disease

BO. Ugut, T. Kahraman, AC. Kalkan, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Association between transfer activities and health-related quality of life in patients with Parkinson’s disease

AC. Kalkan, T. Kahraman, BO. Ugut, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Association of Charcot-Marie-Tooth disease, Parkinson’s disease and FIG4 mutations

I. Posada-Rodríguez, C. Domínguez-González (Madrid, Spain)

1:45pm-3:15pm: Attentional Intervention to Improve Cognition and Gait in Parkinson’s Disease: Side of Onset Effects

A. Cronin-Golomb, O. Barthelemy, A. Marin, B. Davis, S. Alshuaib, T. Ellis, J. Degutis (Boston, MA, USA)

1:45pm-3:15pm: Attitude of Parkinson Patients towards Participation in Clinical Trials and Brain or Tissue Donation for Research

S. Khan, J. Foo, N. Chia, S. Agustin, S. Neo, T. Yaw, A. Lok, A. Ng, L. Tan (Singapore, Singapore)

1:45pm-3:15pm: Automated Metabolic Pattern Analysis in the Differential Diagnosis of Parkinsonism in a Swedish Cohort

I. Markaki, C. Tang, M. Lilja Lindström, D. Eidelberg, P. Svenningsson, I. Savitcheva (Stockholm, Sweden)

1:45pm-3:15pm: Automated Quantitative MRI Biomarkers in Differentiation of Progressive Supranuclear Palsy and Multiple System Atrophy from Parkinson Disease

H. You, Y. Luo, Y. Zhang, H. Wang, B. Hou, L. Shi, F. Feng (Beijing, China)

1:45pm-3:15pm: Availability of levodopa and clinicopathological features of patients with multiple system atrophy

C. Ishida, K. Komai, K. Takahashi, Y. Motozaki, A. Tagami, S. Shibata, M. Asakawa (Kanazawa, Japan)

1:45pm-3:15pm: Awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson’s disease – Insights from an Indian Parkinson’s Registry

N. Sawal, K. Shukla (Chandigarh, India)

1:45pm-3:15pm: Baicalein incorporated nanoliposome disaggregates alpha-synuclein fibrils

F. Aliakbari, D. Morshedi, H. Mohammad-Beigi, D. Otzen (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: Baseline analysis of PROSPECT-M-UK: a longitudinal study of PSP, CBS and MSA

E. Jabbari, J. Woodside, V. Chelban, A. Costantini, N. Holland, N. Leigh, D. Burn, N. Pavese, A. Gerhard, C. Kobylecki, M. Hu, A. Church, J. Rohrer, H. Houlden, J. Rowe, H. Morris (London, United Kingdom)

1:45pm-3:15pm: Baseline hyposmia and RBD symptoms are associated with faster, but differential, cognitive decline at 2 years in the PPMI study

G. Nomikos, J. Xiao, M. Yang, V. Irzhevsky (Cambridge, MA, USA)

1:45pm-3:15pm: Beneficial and protective effects of Terminalia chebula in a murine model of Parkinson’s disease

A. Kumar, S. Farhat (New Delhi, India)

1:45pm-3:15pm: Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson’s disease

YH. Lee, JH. Cha, SJ. Chung, HS. Yoo, YH. Sohn, BS. Ye, PH. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Beyond the Periphery: Central Auditory Processing in Parkinsonian Disorders

E. de Groote, K. de Keyser, A. Bockstael, D. Botteldooren, P. Santens, M. de Letter (Ghent, Belgium)

1:45pm-3:15pm: Bilateral INO in PSP

H. Gupta (Overland Park, KS, USA)

1:45pm-3:15pm: Bilateral vestibulopathy due to neurosarcoidosis mimicking Parkinsonian syndrome

M. Hamaguchi, H. Fujita, K. Suzuki (Utsunomiya, Japan)

1:45pm-3:15pm: Biomarkers of the Level of Cognitive Impairment (CI) in patients with Parkinson’s Disease (PD): MRS study

I. Karaban', N. Karasevich, Z. Rozhkova (Kyiv, Ukraine)

1:45pm-3:15pm: Blood brain barrier dysfunction cause idiopathic adult onset ventriculomegaly?

E. Oh, H. Chang, S. Kim, S. Kim, J. Heo (Daejeon, Republic of Korea)

1:45pm-3:15pm: Body Mass Gain in Parkinson’s Disease Following Deep Brain Stimulation: A Systematic Review

J. Steinhardt, T. Münte, S. Schmid, B. Wilms, N. Brüggemann (Lübeck, Germany)

1:45pm-3:15pm: Braak model in Parkinson disease using MRI biomarkers

N. Pyatigorskaya, L. Yahia-Cherif, R. Valabregue, R. Gaurav, M. Mongin, C. Ewenczyk, C. Gallea, F. Gargouri, E. Bardinet, I. Arnulf, M. Vidailhet, S. Lehericy (Paris, France)

1:45pm-3:15pm: BST1 rs4698412 allelic variant increases the risk of gait or balance deficits in patients with Parkinson’s disease

Y. Shen, J. Wang, K. Zhang (Nanjing, China)

1:45pm-3:15pm: Bumetanide to treat Parkinson’s disease patients suffering from freezing of gait resistant to both dopamine replacement treatment and subthalamic deep brain stimulation: an open-label pilot study (BumFOG)

P. Damier, W. Kamel, J. Al Hashel (Kuwait, Kuwait)

1:45pm-3:15pm: Camptocormia in Parkinson’s disease – impaired kinesthesia of the trunk extensors

R. Wolke, J. Kuhtz-Buschbeck, G. Deuschl, N. Margraf (Kiel, Germany)

1:45pm-3:15pm: Can the Quantified Timed Up and Go (QTUG) device support decision making for patients undergoing Deep Brain Stimulation?

J. Somerset, B. Hammersley, M. Bonello (Liverpool, United Kingdom)

1:45pm-3:15pm: Carotid Intima-Media Thickness and its correlates in people with Parkinson’s disease: a pilot study

S. Castillo-Torres, C. Soto-Rincón, D. Cantú-García, A. Mendoza-Garcia, D. Díaz-Pérez, D. Martínez-Roque, B. Chávez-Luévanos, I. Estrada-Bellmann, F. Góngora-Rivera (Monterrey, Mexico)

1:45pm-3:15pm: Carrier Mediated Delivery System Bearing Dopamine for Effective Management of Parkinsonism

M. Bhargava, S. Bhargava (Kanpur, India)

1:45pm-3:15pm: Case Report: Co-occurrence of Motor Neuron Disease and Parkinsonism

B. Barton (Chicago, IL, USA)

1:45pm-3:15pm: Case-control study of risk developing parkinsonism in Alzheimer’s disease in relation to hypertension, dyslipidemia, and diabetes in Taiwan

W. Lin, PY. Chiu (Changhua, Taiwan)

1:45pm-3:15pm: Cerebellar involvement in progressive supranuclear palsy and corticobasal degeneration

S. Jo, KW. Park, N. Choi, CS. Lee, MS. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Cerebellar rTMS theta burst for postural instability in progressive supranuclear palsy: a double blind cross-over sham controlled study using wearing sensors technology

A. Pilotto, MC. Rizzetti, A. Lombardi, M. Biggi, G. Verzeroli, W. Maetzler, C. Hansen, B. Borroni, A. Padovani (Brescia, Italy)

1:45pm-3:15pm: Cerebellar transcranial magnetic stimulation with neuronavigation for postural instability in PSP

M. George, W. Devries, M. Dale (Charleston, SC, USA)

1:45pm-3:15pm: Cervical and Lumbosacral Spondylosis is common in patients with Parkinsonism in rural Western India

S. Desai (Anand, India)

1:45pm-3:15pm: Characteristics and correlative factors of autonomic dysfunction in Chinese Parkinson’s disease

Z. Zhou, LP. Zhu, XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Y. Yang, LJ. Fang, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Characteristics and outcome of patients with Parkinson’s disease admitted to intensive care unit

O. Benhadj Salem, S. Demeret, A. Demoule, F. Bolgert, H. Outin, T. Sharshar, D. Grabli (Paris, France)

1:45pm-3:15pm: Characteristics of African American Parkinson’s Disease patients seen in a Large Clinic Practice

M. Dean, M. Patel, K. Barnes, D. Standaert (Birmingham, AL, USA)

1:45pm-3:15pm: Characteristics of gait and quality of life in Parkinson’s disease

JW. Kim, SM. Cheon (Busan, Republic of Korea)

1:45pm-3:15pm: CHCHD2 maintains the MICOS and inhibits PINK1/Parkin mediated mitophagy in an experimental model of Parkinson’s disease

X. Chen, M. Zhou, XQ. Zhu, SX. Huang, WY. Guo, Z. Pei, PY. Xu (Guangzhou, China)

1:45pm-3:15pm: Cholecalciferol (VD3) attenuated motor deficits and dyskinesia in Hemi-Parkinsonian mice: behavioural, biochemical & electrophysiological implications

A. Bayo-Olugbami, A. Oyewole, A. Nafiu, A. Amin, B. Ogundele, B. Owoyele, C. Lee (Ilorin, Nigeria)

1:45pm-3:15pm: Circumstances of Falls in Single and Recurrent Fallers with Parkinson’s Disease

I. Castro, H. Cavalcanti, G. Valença, J. Filho, L. Almeida (Salvador, Brazil)

1:45pm-3:15pm: Clear versus conversational speech in Parkinson’s disease, progressive supranuclear palsy, and multiple system atrophy

T. Tykalova, D. Skrabal, J. Klempir, E. Ruzicka, J. Rusz (Prague, Czech Republic)

1:45pm-3:15pm: Clinical and imaging characteristics of manifest LRRK2 and GBA carriers: The PPMI cohort

A. Siderowf, T. Simuni, M. Brumm, L. Uribe, C. Caspell-Garcia, H. Cho, C. Coffey, T. Foroud, B. Mollenhauer, C. Tanner, K. Kieburtz, L. Chahine, D. Weintraub, K. Marek (Chicago, IL, USA)

1:45pm-3:15pm: Clinical and imaging characteristics of non-manifest LRRK2 and GBA carriers: The PPMI cohort

A. Siderowf, T. Simuni, L. Uribe, C. Caspell-Garcia, H. Cho, C. Coffey, T. Foroud, B. Mollehauer, C. Tanner, K. Kieburtz, L. Chahine, D. Weintraub, K. Marek (Philadelphia, PA, USA)

1:45pm-3:15pm: Clinical Associations of Hand Deformities in Parkinson´s Disease

JF. Baizabal-Carvallo, M. Alonso-Juarez, R. Fekete (Valhala, NY, USA)

1:45pm-3:15pm: Clinical comparison of right onset PD vs left onset PD

B. Tserensodnom (Ulaanbaatar, Mongolia)

1:45pm-3:15pm: Clinical features of constipation in patients with Parkinson’s disease: a cross-sectional study in China

LP. Zhu, XT. Zhou, Z. Zhou, LJ. Fang, XX. Zhou, YW. Zhao, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Clinical heterogeneity and neuropathological correlation in progressive supranuclear palsy – description of 4 cases

A. André, M. Malaquias, C. Pinto, M. Calejo, A. Correia, M. Pires, P. Pinto, A. Mendes, M. Magalhães, R. Taipa (Faro, Portugal)

1:45pm-3:15pm: Clinical patterns of gait freezing in Parkinson’s disease and their response to interventions: an observer-blinded study

O. Gavriliuc, S. Paschen, A. Andrusca, C. Schlenstedt, G. Deuschl (Chisinau, Republic of Moldova)

1:45pm-3:15pm: Clinical Response to 72-h Lumbar CSF Drainage in Idiopathic Normal Pressure Hydrocephalus associated with Parkinsonism: Timing and Correlates

G. Mostile, G. Raudino, G. Portaro, F. Certo, A. Nicoletti, G. Barbagallo, M. Zappia (Catania, Italy)

1:45pm-3:15pm: Cognition and Gait in Parkinson’s Disease

A. Fatima (Lahore, Pakistan)

1:45pm-3:15pm: Cognitive dysfunction can predict the body weight loss in patients with Parkinson’s disease

RW. Ou, QQ. Wei, YB. Hou, XQ. Yuan, HF. Shang (Chengdu, China)

1:45pm-3:15pm: Cognitive dysfunction in patients with Parkinson’s disease and psychosis

A. Lenka, S. Hegde, S. Arumugham, R. Yadav, P. Pal (Washington, DC, USA)

1:45pm-3:15pm: Cognitive event related potentials as biomarker of non-motor phenotypes in Parkinson’s Disease

N. Koshel, S. Kryzhanovskyi, N. Karasevych, A. Pisaruk, I. Karaban (Kyiv, Ukraine)

1:45pm-3:15pm: Cognitive impairment in patients with Parkinson’s syndrome

SH. Rakhimova, I. Usmonaliev, Y. Musaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease

F. Adib Saberi, D. Dressler (Hamburg, Germany)

1:45pm-3:15pm: Comorbid Parkinson’s disease and Myasthenia Gravis: A Case-Control Study

K. Lafaver, D. Mohanty, C. Bodkin, M. Brown, A. Druker, J. Farmer, J. Fleisher, I. Gambhir, T. Harlow, F. Leon-Sarmiento, C. Perry, Z. Wang, A. Espay (Louisville, KY, USA)

1:45pm-3:15pm: Comorbid Parkinson’s disease in a Korean patient with Alexander’s disease

KY. Kwon, JW. Cho, JK. Park (Seoul, Republic of Korea)

1:45pm-3:15pm: Comparative Grey and White Matter Tau Pathology in LBD and PSP using Digital Histologic Measurements

D. Coughlin, C. Petersen, R. Lobrovich, D. Wolk, A. Siderowf, D. Weintraub, E. Lee, J. Trojanowski, M. Grossman, D. Irwin (Philadelphia, PA, USA)

1:45pm-3:15pm: Comparison of motor, non motor symptoms, impulse control disorders and quality of life in patients with young versus late onset Parkinson’s disease

S. Meka, R. Kandadai, T. Syed, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: Compensatory Amygdala Activity during motor timing and selection in PD

SPD. Allahdadian, H. Rafipoor, E. Yargholi, M. Mirian, MJM. Mckeown (Vancouver, BC, Canada)

1:45pm-3:15pm: Comprehensive clinico-pathophysiological assessment of constipation in Parkinson’s disease

E. de Pablo-Fernandez, V. Passananti, N. Zárate-López, A. Emmanuel, T. Warner (London, United Kingdom)

1:45pm-3:15pm: Computing algorithms can detect bradykinesia from smartphone videos

S. Williams, H. Fang, D. Wong, S. Relton, C. Graham, J. Alty (Leeds, United Kingdom)

1:45pm-3:15pm: Concentration of short chain fatty acids in the peripheral blood of patients with Parkinson disease

C. Shin, Y. Lim, TB. Ahn (Seoul, Republic of Korea)

1:45pm-3:15pm: Concomitant brain pathologies have no major impact on clinical milestones in progressive supranuclear palsy

M. Jecmenica-Lukic, C. Kurz, G. Respondek, O. Grau-Rivera, Y. Compta, E. Gelpi, C. Troakes, J. van Swieten, A. Giese, S. Roeber, T. Arzberger, G. Höglinger (Munich, Germany)

1:45pm-3:15pm: Constipation with selected prodromal features increases risk of subsequent Parkinson’s Disease

E. Brown, S. Goldman, K. Albers, S. Vanden Eeden, C. Tanner (San Francisco, CA, USA)

1:45pm-3:15pm: Continuous dopaminergic treatment with levodopa/carbidopa intestinal gel in multiple system atrophy: report of three patients

S. Delalic, S. Ibrulj, N. Zupancic, D. Flisar, M. Trost, Z. Pirtosek, M. Kojovic (Ljubljana, Slovenia)

1:45pm-3:15pm: Contribution of pedunculopontine nucleus cholinergic neurons to L-DOPA-induced dyskinesia and PD motor deficits in hemi-parkinsonian rats

N. Chambers, J. Sergio, C. Saito, K. Lanza, C. Bishop (Binghamton, NY, USA)

1:45pm-3:15pm: Corneal confocal microscopy: An imaging biomarker of neurodegeneration in Parkinson’s disease

M. Silverdale, I. Petropoulos, A. Kalteniece, R. Malik, C. Kobylecki, M. Ferdousi, S. Lim (Salford, United Kingdom)

1:45pm-3:15pm: Correlation between Pareidolia and cerebral perfusion by SPECT in Parkinson’s disease without dementia: A retrospective study

H. Akamine, T. Tokashiki (Ginowan, Japan)

1:45pm-3:15pm: Correlation Between PDQ-39 and MDS-UPDRS Scores in a Phase 3 Randomized Controlled Trial of Patients with Parkinson’s Disease

T. Lokhandwala, A. Lee, B. Yue, A. Thach, B. Navia (Palm Harbor, FL, USA)

1:45pm-3:15pm: Cortical FDG-PET patterns predict long-term motor progression and disability milestones in Parkinson’s disease

A. Pilotto, A. Imarisio, E. Premi, SP. Caminiti, L. Presotto, A. Sala, R. Turrone, R. Grasso, A. Alberici, B. Paghera, MC. Rizzetti, B. Borroni, D. Perani, A. Padovani (Brescia, Italy)

1:45pm-3:15pm: Cortical thickness analysis in Parkinson’s disease with urinary symptoms

R. Roh, K. Kim, K. Koh (Seoul, Republic of Korea)

1:45pm-3:15pm: Cough sensitivity and aspiration pneumonia in Parkinson’s disease

S. Tomita, T. Oeda, S. Takaya, M. Kohsaka, K. Park, A. Umemura, Y. Mori, T. Ishihara, S. Nomoto, M. Tahara, K. Yamamoto, H. Sawada (Kyoto, Japan)

1:45pm-3:15pm: CXCL12 is involved in α-synuclein-triggered neuroinﬂammation of Parkinson’s disease

Y. Li, M. Niu, J. Liu (Shanghai, China)

1:45pm-3:15pm: Daytime Sleepiness Effects on Motor Symptoms in De Novo Parkinson’s Disease

E. Bayram, R. Yilmaz, K. Longardner, M. Akbostanci, I. Litvan (La Jolla, CA, USA)

1:45pm-3:15pm: DBS Programming In Tremor And Akinetic-Rigid Predominant Parkinson’s Disease

Z. Guduru, D. Ginjupally, T. Ali, N. El Seblani, J. Quintero, C. van Horne (Lexington, KY, USA)

1:45pm-3:15pm: DCM extract of Scutellaria Pinnatifida modulate alpha-synuclein fibrillation and protects dopaminergic SH-SY5Y cells against rotenone

S. Parsafar, D. Morshedi, M. Mohammadi (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: Deciphering Corticobasal Syndrome: are clinical features and FDG-PET imaging capable of predicting amiloyd status?

J. Parmera, A. Coutinho, A. Neto, M. Aranha, C. Ono, C. Buchpiguel, R. Nitrini, E. Barbosa, S. Brucki (São Paulo, Brazil)

1:45pm-3:15pm: Deciphering the role of posttranslational modifications on α-synuclein aggregation and toxicity

T. Outeiro (Goettingen, Germany)

1:45pm-3:15pm: Deep Brain Stimulation as second line advanced treatment for PD after LCIG

A. Faust-Socher, F. Abu Ahmad, N. Giladi, A. Hilel, Y. Shapira, D. Klepikov, A. Ezra, L. Raif, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Deep Brain Stimulation for atypical tremors secondary to Neuroferritinopathy: Single center experience

S. Chandra, J. Randhawa, M. Schiess (Houston, TX, USA)

1:45pm-3:15pm: Deep Brain Stimulation Wash-in/out Periods Quantified using a Palm-Worn Device to Monitor Rigidity

T. Perera, WL. Lee, M. Jones, J. Tan, E. Proud, A. Begg, N. Sinclair, R. Peppard, H. Mcdermott (East Melbourne, Australia)

1:45pm-3:15pm: Deep mitochondrial sequencing in Parkinson’s disease reveals possible genetic modifiers of reduced penetrance in Parkin/PINK1 mutation carriers

J. Trinh, A. Hicks, K. Wasner, M. Farrer, F. Hentati, P. Bauer, S. Imhoff, K. Kandaswamy, N. Ouzren, M. Werber, A. Rolfs, V. Kostic, A. Lang, P. Pramstaller, P. Seibler, K. Lohmann, A. Gruenewald, C. Klein (Luebeck, Germany)

1:45pm-3:15pm: Demographic Influences on Wearing Off Symptoms in Parkinson’s Disease

L. Chahine, G. Cummin, S. Chen, J. Buchanich, B. Edison, M. Daeschler, S. Kahl, C. Kopil, C. Marras (Toronto, ON, Canada)

1:45pm-3:15pm: Detection of impaired finger dexterity by objective keyboard typing test in Parkinson’s Disease: A feasibility study

P. Panyakaew, K. Duangjino, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Diagnostic accuracy of Progressive Supranuclear Palsy: Experience of a movement disorders center

M. Gultekin (Kayseri, Turkey)

1:45pm-3:15pm: Differences in resting state fMRI distinguish multiple system atrophy and Parkinson disease

A. Peterson, E. Dayan, N. Browner, D. Drazheva, M. Sklerov (Chapel Hill, NC, USA)

1:45pm-3:15pm: Differential Value of Brain Magnetic Resonance Imaging in MSA-C and SCAs

M. Kim, JK. Mun, JH. Ahn, JS. Kim, J. Youn, JW. Cho (Seoul, Republic of Korea)

1:45pm-3:15pm: Differentiation of Progressive Supranuclear Paralysis from Multisystem Atrophy and Parkinson’s Disease by Cranial MRI

E. Natera-Villalba, V. Ros-Castelló, A. Sánchez-Sánchez, A. Gómez-López, P. Pérez-Torre, JL. López Sendón, I. Parées-Moreno, JC. Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)

1:45pm-3:15pm: Diplopia and visual complaints in non-demented patients with Parkinson disease: a Japanese single center cross-sectional survey

K. Ota, K. Takahashi, K. Seo, H. Kawasaki, K. Ikeda, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, N. Tamura, N. Araki, T. Yamamoto (Saitama-Ken, Japan)

1:45pm-3:15pm: Discriminative power of different olfactory domains in Parkinson’s disease

YW. Zhao, RC. He, JX. Yang, Y. Zhang, XT. Zhou, XX. Zhou, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Do non-motor fluctuations temporarily match ON/OFF motor condition?

E. Del Prete, E. Schmitt, S. Meoni, V. Fraix, A. Castrioto, P. Pelissier, R. Ceravolo, E. Moro (Grenoble, France)

1:45pm-3:15pm: Does Anticholinergic Burden Affect the Outcomes in Patients Diagnosed with Parkinson’s Disease?

S. Taylor, E. Jones (York, United Kingdom)

1:45pm-3:15pm: Does automated analysis of repeat DaTscan imaging aid diagnosis in suspected Lewy body disorders?

F. Richardson, N. Vennart, P. Bartholomew, C. Mcdonald (Gateshead, United Kingdom)

1:45pm-3:15pm: Does the truth lie within the gut? Investigating the gut microbiome in an Australian cohort of Parkinson’s disease patients

J. Kenna, S. Mcgregor, M. Horne, A. Tay, S. Ghosh, F. Mastaglia, A. Jefferson, A. Gorecki, M. Bakeberg, S. Walters, R. Anderton (Perth, Australia)

1:45pm-3:15pm: Does Transcranial Direct Current Simulation Improve Motor Functions in Patients with Parkinson’s disease?

E. Bahbah, M. Morsi, M. Aziz, A. Hassanen, A. Ali, M. Abdelmongy, M. Sinokrot, A. Negida, A. Shalash (Damietta, Egypt)

1:45pm-3:15pm: Drooling in Parkinson’s Disease: A [123I]FP-CIT SPECT study

V. Suarez Contreras, Y. Tayyabah, S. Caminiti, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Drug Utilization in a Real World Cohort with Progressive Supranuclear Palsy

G. Hoeglinger, D. Oleske, J. Zamudio, R. Diegidio, J. Holman (Munich, Germany)

1:45pm-3:15pm: Dry eye in Parkinson’s disease: symptoms, consequences and treatment options

I. Csoti, N. Koleva-Alazeh (Leun, Germany)

1:45pm-3:15pm: Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)

E. Pourcher, A. Corbin, J. Qian, C. Kenney (Quebec City, QC, Canada)

1:45pm-3:15pm: Dysregulated long non-coding RNA in Parkinson’s disease contributes to the apoptosis of dopaminergic neuron

Y. Fan, Z. Xue (Wuhan, China)

1:45pm-3:15pm: Early diagnosis of progressive supranuclear palsy using quantitative MRI analysis of brain structure

K. Seo, T. Yamamoto, H. Kawasaki, T. Hukuoka, Y. Nakazato, K. Takahashi, I. Matunari, H. Matuda, N. Tamura, N. Araki (Saitama, Japan)

1:45pm-3:15pm: Early Impairment of Chopsticks Skill Predict Atypical Parkinsonism

YE. Kim, H. Ma, YJ. Kim (Anyang-Si, Republic of Korea)

1:45pm-3:15pm: Early postural instability is an effective predictor of future freezing of gait in Parkinson’s disease

J. Lee (Goyang-Si, Republic of Korea)

1:45pm-3:15pm: Early stage Parkinson’s disease patients with GBA mutation have more severe motor symptoms and difficult to differentiate in routine clinical practice

S. Abe, K. Komatsu, H. Satoi, H. Saiki, Y. Oka (Osaka, Japan)

1:45pm-3:15pm: Effect of a Combined Treatment with Botulinum Toxin and Biofeedback Exercises in Pisa Syndrome

A. Castagna, A. Crippa, D. Anastasi, M. Meloni, A. Montesano, A. Marzegan (Milano, Italy)

1:45pm-3:15pm: Effect of Levodopa on gut microbiome in Parkinson’s Disease (PD)

A. Hannoun, D. Ward, J. Flahive, J. Friedman, A. Deb, K. Smith (Worcester, MA, USA)

1:45pm-3:15pm: Effectiveness of exome sequencing in Parkinson’s disease of Chinese population

YW. Zhao, HX. Pan, L. Jiang, Y. He, Q. Zeng, XT. Zhou, XX. Zhou, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Effects of levodopa on LTP-like plasticity induced by quadripulse magnetic stimulation in Parkinson’s disease

S. Moriyasu, T. Shimizu, T. Honda, Y. Ugawa, R. Hanajima (Yonago, Japan)

1:45pm-3:15pm: Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease

C. Olanow, F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, R. Kleiman, D. Blum, B. Navia (New York, NY, USA)

1:45pm-3:15pm: Enhancing the Proteasomal Degradation of Alpha Synuclein: “The Hallmark” to attenuating the Progression of Parkinson’s Disease

B. Adebisi, M. Adeleke (Osogbo, Nigeria)

1:45pm-3:15pm: Estimating the long-term effect of early levodopa treatment initiation in Parkinson’s disease

L. Vd Heuvel, J. Krijthe, L. Evers, M. Meinders, B. Post, T. Heskes, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Evaluation of bedside screening tests to detect dysphagia in Parkinson’s disease

F. Brugger, J. Walch, M. Galovic, S. Hägele-Link, S. Stöckli, M. Müller-Baumberger, G. Kägi (St. Gallen, Switzerland)

1:45pm-3:15pm: Evaluation of Clinical Peculiarities of Violations of Vertical Vision in Patients with Parkinson’s Disease

M. Salokhiddinov, D. Akramova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Evaluation of Constipation in Patients with Parkinson’s Disease and its Correction

M. Salokhiddinov, D. Akramova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Evaluation of dose rate of photobiomodulation (light) therapy in patients with Parkinson’s Disease: Double blind placebo-controlled pilot trial. Is there a dose frequency per week that influences quality of life, mobility and cognition?

J. Bullock-Saxton, L. Laakso, A. Lehn, F. Read, K. Harm, A. Gosling, S. Hardy, P. Newcombe, A. Nolan, E. Tune (Brisbane, Australia)

1:45pm-3:15pm: Examining level of hemoglobin in patients with parkinson’s disease and the role of hemoglobin level in the disease course

SH. Shohimardonov, K. Daminova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Exercise and physical activity for people with Progressive Supranuclear Palsy

S. Slade, D. Finkelstein, J. Mcginley, M. Morris (Ivanhoe, Australia)

1:45pm-3:15pm: Exosomes from patients with Parkinson’s disease are pathological in mice

C. Han, N. Xiong, X. Guo, J. Huang, K. Ma, L. Liu, Y. Xia, S. Yin, L. Kou, F. Wan, J. Hu, G. Zhang, T. Wang (Wuhan, China)

1:45pm-3:15pm: Exploratory Analysis of Electrocortical Signal Complexity in Patients with Progressive Supranuclear Palsy and Corticobasal Degeneration

G. Mostile, L. Giuliano, R. Terranova, A. Luca, G. Donzuso, G. Portaro, C. Rascunà, V. Sofia, A. Nicoletti, M. Zappia (Catania, Italy)

1:45pm-3:15pm: Factors Affecting Mortality in Late Stage Parkinson’s Disease

S. Dempsey, L. Mcdonald, I. Sayers, WK. Gray, A. Hand, R. Walker (Newcastle Upon Tyne, United Kingdom)

1:45pm-3:15pm: Factors associated with dyskinesia in Parkinson’s disease in Mainland China

X. Zhou, LF. Fang, XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Fall History and Gait Variability can Predict Falls in Individuals With Parkinson’s Disease

L. Ma, P. Chan (Beijing, China)

1:45pm-3:15pm: Frailty in Parkinson’s disease: A systematic review

N. Smith, L. Brennan, D. Gaunt, Y. Ben-Shlomo, E. Henderson (Bath, United Kingdom)

1:45pm-3:15pm: Freezing of gait as a reflection of disturbed general time processing in Parkinson’s disease? A new look on a complex phenomenon

J. Wagner, A. Gulberti, J. Verrel, S. Tunc, T. Bäumer, W. Hamel, AK. Engel, C. Gerloff, CKE. Moll, A. Münchau, M. Pötter-Nerger (Hamburg, Germany)

1:45pm-3:15pm: Frequency of impulse control disorder in Parkinson’s disease: insights from the Luxembourg cohort

S. Binck, C. Pauly, P. Kolber, L. Pavelka, L. Stute, D. Reiter, M. Vaillant, M. Gantenbein, E. Glaab, J. Ferrand, L. Geffers, G. Hipp, R. Krueger, NJ. Diederich (Strassen, Luxembourg)

1:45pm-3:15pm: Functional Limits of Stability and Standing Balance in people with and without Freezing of Gait

N. Hasegawa, K. Maas, V. Shah, P. Carlson-Kuhta, J. Nutt, F. Horak, T. Asaka, M. Mancini (Portland, OR, USA)

1:45pm-3:15pm: Functional mobility tests and their relationship with disease stage in patients with Parkinson’s Disease

B. üğüt, T. Kahraman, A. Kalkan, A. Genç, B. çolakoğlu (Izmir, Turkey)

1:45pm-3:15pm: Gait impairment in Parkinson’s Disease: An [123I]FP-CIT SPECT study

V. Suarez Contreras, Y. Tayyabah, S. Caminiti, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Gaze – evoked nystagmus in PSP patients: Is it really atiypical? A case series of eight patients

MK. Klarendic, MA. Hribar, SB. Battelino, MGK. Kramberger, MK. Kojovic (Ljubljana, Slovenia)

1:45pm-3:15pm: GBA-LRRK2 Parkinson’s Disease: a clinical case

L. Azevedo Kauppila, D. Pimenta Silva, A. Castro Caldas, M. Coelho, J. Ferreira, L. Correia Guedes (Lisboa, Portugal)

1:45pm-3:15pm: Gender differences in Motor symptoms, Non-Motor symptoms and Quality of Life in Parkinson’s disease: COPPADIS-2015 study cohort

M. Aguilar, P. Pastor, B. Solano, I. Cabo, MJ. Catalan, V. Nogueira, V. Puente, JM. Garcia, R. Perez, C. Borrué, M. Mata, M. Alvarez, AB. Rodriguez, L. Vela, Y. Macías, MJ. Marti, P. Martinez, D. Santos (Sabadell, Spain)

1:45pm-3:15pm: Gender differences of fatigue characteristics in people with Parkinson’s disease

G. Cilga, T. Kahraman, AC. Kalkan, B. Donmez Colakoglu, A. Genc (Manisa, Turkey)

1:45pm-3:15pm: Gender-specific effects of uric acid on the development of freezing of gait in Parkinson’s disease

JH. Jung, SJ. Chung, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Genetics and phenotypes of recessive parkinsonism in French and North African populations

S. Lesage, A. Lunati, M. Houot, S. Benromdhan, C. Tesson, F. Clot, C. Mhiri, E. Lohmann, JC. Corvol, A. Brice (Paris, France)

1:45pm-3:15pm: Genomic variants associated with cognitive impairment in Parkinson’s disease: Ethnicity-specific GWAS

SJ. Chung, N. Choi, J. Kim, K. Kim, MJ. Kim, YJ. Kim, HS. Ryu, KW. Park (Anyang, Republic of Korea)

1:45pm-3:15pm: Glabellar tap predicts dopamine transporter deficiency in parkinsonism

S. Nuuttila, J. Joutsa, M. Eklund, E. Jaakkola, E. Mäkinen, T. Noponen, T. Ihalainen, F. Scheperjans, V. Kaasinen (Turku, Finland)

1:45pm-3:15pm: Gray matter atrophy in Parkinson’s disease and freezing of gait assessed using surface-based algorithm – results of an open, longitudinal, single-centre study

P.. Kanovsky, M.. Vastik, K.. Mensikova, P.. Hok, J.. Valosek, P.. Hlustik (Olomouc, Czech Republic)

1:45pm-3:15pm: Harmonics: A reliable marker in tremor analysis for the differential diagnosis of Parkinson’s disease and multiple system atrophy

D. Su, S. Yang, J. Zhou, H. Pan, T. Feng (Beijing, China)

1:45pm-3:15pm: Healthcare disparities in patients with Parkinson’s disease: A comprehensive literature review and call to action

S. Naik, V. Holiday, L. Dixon, M. Kolikonda, K. Lafaver (Louisville, KY, USA)

1:45pm-3:15pm: Heterogeneous patterns of striatal dopamine loss in patients with young- versus old-onset Parkinson’s disease

NE. Woo, SJ. Chung, HS. Yoo, YH. Lee, PH. Lee, YH. Sohn (Seoul, Republic of Korea)

1:45pm-3:15pm: High cost of medications for Parkinson’s Disease patients in a rural population of Gujarat, India

A. Pandya, E. Albert-Stone, A. Deb, S. Desai (Worcester, MA, USA)

1:45pm-3:15pm: High intensity interval training elevates circulating BDNF and miRNAs level in patients with idiopathic Parkinson’s disease

P. Malczynska, B. Kaminski, M. Siemiatycka, A. Pawłowska, I. Przybylska, J. Langfort, J. Marusiak, M. Chalimoniuk (Warsaw, Poland)

1:45pm-3:15pm: High repressive activity of olive extracts on the cell line model of Parkinson disease against ROS induction

D. Morshedi (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: High-throughput screening using a Drosophila model of Parkinson’s disease

FJ. Lopez, C. Solana, E. Masia, MJ. Vicent, N. Paricio (Valencia, Spain)

1:45pm-3:15pm: Hip fracture in patients with a new diagnosis of Parkinson’s Disease – estimating the 5-year risk

L. Evans, A. Johansen, B. Mohamed, EC. Thomas (Cardiff, United Kingdom)

1:45pm-3:15pm: Hoover’s Sign in Parkinson’s Disease

A. Vasilenko, M. Karpova (Chelyabinsk, Russian Federation)

1:45pm-3:15pm: Hydrocephalic presentation of PSP and follow-up after ventricular-peritoneal shunting: Case report

A. Taskinbayeva, CH. Shashkin, R. Kaiyrzhanov (Almaty, Kazakhstan)

1:45pm-3:15pm: Hypothalamic functional connectivity correlates with autonomic symptom burden in patients with Multiple System Atrophy

M. Sklerov, N. Browner, D. Drazheva, E. Dayan (Chapel Hill, NC, USA)

1:45pm-3:15pm: Identification of potential new genes involved in autosomal recessive forms of Parkinson’s disease

C. Tesson, A. Honoré, V. Drouet, H. Bertrand, S. Lesage, A. Brice (Paris, France)

1:45pm-3:15pm: Identification of protein biomarker/s in CSF of Parkinson’s disease (PD) with cognitive impairment

A. Naskar, A. Stezin, D. Gadara, S. Ahuja, V. Menon, N. Kamble, J. Saini, S. Hegde, U. Tatu, P. Pal, P. Alladi (Bangalore, India)

1:45pm-3:15pm: Identifying genetic Parkinson’s disease patients worldwide: Exploiting novel ways of team science

E-J. Vollstedt, M. Kasten, C. Klein (Lübeck, Germany)

1:45pm-3:15pm: Identifying healthy Parkin mutation carriers based on sensor-based posturography and gait analysis

J. Prasuhn, M. Borsche, A. Hicks, M. Gögele, C. Egger, C. Kritzinger, L. Langlott, M. Kasten, C. Klein, P. Pramstaller, N. Brüggemann (Lübeck, Germany)

1:45pm-3:15pm: Identifying Incident Cases of Neurodegenerative Parkinsonism in a Large Observational At-Risk Cohort: the PPMI study

L. Chahine, K. Kieburtz, M. Brumm, C. Caspell-Garcia, C. Coffey, A. Siderowf, D. Weintraub, C. Tanner, T. Foroud, D. Galasko, B. Mollenhauer, T. Simuni, K. Marek (Pittsburgh, PA, USA)

1:45pm-3:15pm: Identifying perceptual, motor and cognitive components contributing to the slowness of information processing in Parkinson’s disease and the implication in the quality of life

A. Arroyo, J. Andreo, J. Periañez, G. Lubrini, M. Rios, JP. Romero (Pozuelo de Alarcon, Spain)

1:45pm-3:15pm: Impact of a high-fat diet on the behavior of A53T alpha-Synuclein Parkinson’s disease mice

M. Temmel, V. Niederkofler, R. Rabl, H. Roemer, B. Hutter-Paier (Grambach, Austria)

1:45pm-3:15pm: Impact of OFF periods on aspects of employment for people with Parkinson’s disease

I. Iresha Abeynayake, L. Marinucci, M. Klingler, C. Kenney (Aardsley, NY, USA)

1:45pm-3:15pm: Impact of overweight and obesity on functional and clinical outcomes of early Parkinson’s disease

R. Kim, JS. Jun (Seoul, Republic of Korea)

1:45pm-3:15pm: Impact of quantitative assessment of parkinsonian symptoms using wearable technology on treatment decisions

C. Thomas, B. Mohamed, M. Silverdale, C. Kobylecki, L. Osborne, R. Saha, P. Bain, D. Heisters, C. Carroll (Cardiff, United Kingdom)

1:45pm-3:15pm: Impaired lysosomal catabolism of alpha-synuclein in parkinsonian LRRK2(R1441G) mutant mouse embryonic fibroblasts

WL. Ho, CT. Leung, HF. Liu, LF. Li, DB. Ramsden, SL. Ho (Hong Kong, Hong Kong)

1:45pm-3:15pm: Improving neuroprotective effects of resveratrol by brain targeting through chitosan glutamate nanoparticles in MPTP induced parkinsonism

M-R. Rahman, V-K. Kumar (Allahabad, India)

1:45pm-3:15pm: Improving outcomes in hospitalized Parkinson’s patients

S. Aslam, E. Simpson, M. Baugh, H. Shill (Phoenix, AZ, USA)

1:45pm-3:15pm: Impulse control disorders and (romantic) jealousy in Parkinson’s disease: a patients’ vs. partners’ perspective

E. Pipan, S. Delalić, A. Herzog, M. Trošt, Z. Pirtošek, D. Flisar, N. Kovacs, D. Georgiev (Ljubljana, Slovenia)

1:45pm-3:15pm: Incidence of drooling in Parkinson’s Disease and Impact on Quality of Life

B. Gibbons, B. Mohamed, C. Thomas (Cardiff, United Kingdom)

1:45pm-3:15pm: Increased lysosphingolipids levels in blood of patients with multiple system atrophy

K. Senkevich, G. Baydakova, A. Emelyanov, M. Nikolaev, A. Kopytova, I. Miliukhina, E. Gracheva, A. Kudrevatykh, I. Krasakov, L. Khublarova, I. Fursova, Y. Irishina, N. Zalutskaya, Y. Beltseva, E. Zakharova, S. Pchelina (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: Increased vesicular monoamine transporter alleviate MPTP-induced impairment of neurogenesis

K. Ma, G. Zhang, C. Han, X. Guo, Y. Xia, F. Wan, L. Kou, S. Yin, L. Liu, N. Xiong, J. Huang, T. Wang (Wuhan, China)

1:45pm-3:15pm: Influence of peripheral immune system on cognitive profile in Parkinson’s disease

L. Magistrelli, E. Storelli, V. Milner, E. Rasini, F. Marino, M. Cosentino, C. Comi (Varese, Italy)

1:45pm-3:15pm: Influence of spatial filtering on EEG signal stochasticity measurements in Parkinson’s Disease

D. Herraez-Aguilar, A. Maitín, R.. Perezzan, D. Del Castillo, I. Serrano, E. Rodríguez, E. Rocon, A. Arroyo, J. Andreo, J. Romero (Pozuelo de Alarcon, Spain)

1:45pm-3:15pm: Inhibitory Repetitive Transcranial Magnetic Stimulation of Pre-Supplementary Motor Area Improves Levodopa-Induced Dyskinesia in Parkinson’s Disease

A. Lohse, D. Meder, D. Herz, A. Løkkegaard, H. Siebner (Copenhagen, Denmark)

1:45pm-3:15pm: Interleaving stimulation in Parkinson’s disease: interesting to whom?

C. França, E. Barbosa, R. Iglesio, M. Teixeira, R. Cury (São Paulo, Brazil)

1:45pm-3:15pm: Investigating Physical and Cognitive Changes over Two Years in Patients with Moderate to Late Stage Parkinson’s Disease in Northumbria

L. Macdonald, I. Sayers, S. Dempsey, W. Gray, A. Hand, R. Walker (North Shields, United Kingdom)

1:45pm-3:15pm: Investigating the cellular role of LRRK2 in the immune system

I. Nazish, R. Bandopadhyay (London, United Kingdom)

1:45pm-3:15pm: Is safinamide helpful in multiple system atrophy?

R. Simões, A. Gonçalves, JJ. Ferreira (Lisboa, Portugal)

1:45pm-3:15pm: Is the personal Kinetigraph useful in the management of Parkinson´s disease patients? A retrospective study from a tertiary movement disorder center

E. Krause, J. Randhawa, R. Mehanna (Houston, TX, USA)

1:45pm-3:15pm: K0706, A Potent Orally Bioavailable Brain-Penetrating Selective Inhibitor of cABL Protein Tyrosine Kinase, Exhibits Neuroprotective Activity in Preclinical Models of Parkinson’s Disease

S. Mandhane, D. Soni, K. Jani, P. Sengupta, A. Patel, R. Bambal, V. Ramanathan, Y. Zala, N. Dharmadhikari, C. Rao, A. Raghavan, N. Damle (Vadodara, India)

1:45pm-3:15pm: Language disorders in Progressive Supranuclear Palsy: an underestimated condition?

E. Del Prete, L. Tommasini, D. Frosini, S. Mazzucchi, C. Pagni, U. Bonuccelli, R. Ceravolo (Pisa, Italy)

1:45pm-3:15pm: Left STN DBS And Right CZI DBS In A Patient With Tremor-Predominant Parkinson’s Disease

T. Ali, D. Ginjupally, G. Quintero, C. van Horne, Z. Guduru (Lexington, KY, USA)

1:45pm-3:15pm: Levodopa Induced dyskinesia in patients with Parkinson’s disease and polymorphisms gene DRD3 dopamine receptor

I. Zhukova, N. Zhukova, E. Kolupaeva, S. Ivanova, M. Nikitina, O. Izhboldina, I. Mironova (Tomsk, Russian Federation)

1:45pm-3:15pm: Levodopa response in later stages of Parkinson’s disease: a case-control study

M. Fabbri, M. Coelho, D. Abreu, L. Guedes, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)

1:45pm-3:15pm: Levodopa-carbidopa intestinal gel infusion: a video analysis of long-term effect on gait and posture

C. Pongmala, M. Fabbri, CA. Artusi, M. Zibetti, L. Lopiano (Turin, Italy)

1:45pm-3:15pm: Limitations of Curcumin as a Therapeutic Agent in Rotenone Induced Dopaminergic Neurodegeneration: Insights from Drosophila Model of Parkinson’s Disease

M. Ayajuddin, SC. Yenisetti (Zunheboto, India)

1:45pm-3:15pm: Lip movement contribution in speech production of persons with Parkinson’s Disease

P. Upadhyay, S. Gudwani, K. Sharma, R. Sagar, R. Dhamija, S. Kumaran (New Delhi, India)

1:45pm-3:15pm: Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world

A. Panwar, N. Sawal (Chandigarh, India)

1:45pm-3:15pm: Long-term adherence with wearing a multi-sensor watch in the Personalized Parkinson Project

L. Evers, R. Kapur, T. V.D. Zande, M. Meinders, B. Bloem, W. Marks, JR. (Nijmegen, Netherlands)

1:45pm-3:15pm: Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease

M. Fabbri, P. Chatkaew, C. Artusi, A. Romagnolo, M. Rizzone, M. Zibetti, L. Lopiano (Turin, Italy)

1:45pm-3:15pm: Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease

M. Schiess, M. Doursout, J. Campo, Z. Peng, A. Sundaresan, S. Umar (Lawrence, KS, USA)

1:45pm-3:15pm: Longitudinal assessment of genetic determinants of cognitive decline in Parkinson’s disease

M. Bakeberg, A. Jefferson, M. Byrnes, S. Ghosh, F. Mastaglia, R. Stell, J. Kenna, S. Walters, M. Hoes, A. Ford, R. Anderton (Nedlands, Australia)

1:45pm-3:15pm: Longitudinal progression of spatiotemporal parameters of turning in idiopathic Parkinson’s disease patients with Freezing of Gait

L. Pillai, A. Glover, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm: Longstanding cervical dystonia followed by parkinsonism – coincidence, risk factor or syndromic association?

B. Balint, F. Gövert, A. Latorre, E. Mulroy, R. Erro, A. Batla, T. Warner, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Machine learning classifiers and subjective vocal perception of Parkinson’s disease patients and healthy control

Y. Manor, S. Naor, D. Shpunt, N. Diamant, A. Hillel, A. Ezra, I. Opher, Y. Hauptman, R. Aloni-Lavi, A. Faust-Socher, H. Shabtai, R. Peled, A. Migirov, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Measuring perceived-health status in Parkinson’s Disease – the role of London Handicap Scale

D. Silva, M. Coelho, T. Soares, T. Vale, L. Guedes, R. Maciel, A. Antunes, S. Camargos, A. Valadas, C. Godinho, D. Maia, P. Lobo, R. Maia, T. Teodoro, C. Rieder, A. Velon, M. Rosas, A. Calado, V. Caniça, F. Cardoso, J. Ferreira (Lisbon, Portugal)

1:45pm-3:15pm: Measuring progression of nigrostriatal degeneration in Parkinson’s disease using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET

S. Xu, V. Dore, P. Alexander, Y. Lie, S. Bozinovski, R. Mulligan, K. Young, V. Villemagne, C. Rowe (Melbourne, Australia)

1:45pm-3:15pm: Medical and Device-Guided Therapies and Deep Brain Stimulation in Parkinson’s disease: Experience of a Tertiary Centre from Turkey

Y. Sucullu Karadag, D. Divanlıoglu, E. Kocabicak, N. Subutay Oztekin, D. Belen (Ankara, Turkey)

1:45pm-3:15pm: Medical management after subthalamic nucleus deep brain stimulation in patients with Parkinson’s Disease

A. Bertholo, R. Cury (São Paulo, Brazil)

1:45pm-3:15pm: Memantine and 3D gait analysis in patient with Parkinson’s disease: an observer-blind randomized clinical trial

I. Miliukhina, E. Gracheva (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: Memory enhancing effect of Combined Alcoholic Extract of Cedrus deodara Loud. and Vitex Nirgundi in scopolamine-induced cognitive impairment in mice

A. Jain, S. Jain (Sagar, India)

1:45pm-3:15pm: Metabolic syndrome and insulin resistance in Parkinson’s disease: could they affect motor or cognitive symptoms?

M. Hussein, A. Khamis, R. Soliman, S. Ali (Beni Suef, Egypt)

1:45pm-3:15pm: Modifiable factors and progression of motor symptoms and cognitive decline in Parkinson’s disease

E. Forbes, T. Tropea, S. Mantri, J. Morley (Philadelphia, PA, USA)

1:45pm-3:15pm: Modulation of cerebellar and basal ganglia loops affects vestibular processing in Parkinson’s disease

J. Liao, C. Mcintyre, A. Shaikh (Cleveland, OH, USA)

1:45pm-3:15pm: Monitoring Parkinson’s disease symptoms during daily life: A feasibility study

M. Heijmans, J. Habets, C. Herff, M. Kuijf, P. Kubben (Maastricht, Netherlands)

1:45pm-3:15pm: Motor and Non-Motor Symptom Burden in Parkinsonian and Cerebellar Phenotypes of Probable MSA

M R. Rukmani, R. Yadav, P K. Pal, B. Bhaskarapillai, T N. Sathyaprabha (Bangalore, India)

1:45pm-3:15pm: Motor and non-motor symptoms in the prediagnostic phase of progressive supranuclear palsy: the Step-Back PSP study.

C. Painous, C. Simonet, A. Garrido, N. Caballol, M. Guasp, A. Cámara, F. Valldeoriola, JE. Muñoz, MJ. Martí, Y. Compta (Barcelona, Catalonia)

1:45pm-3:15pm: Motor Response Inhibition – A potential tool to determine optimum STN-DBS setting

H. Kumar, A. Roy, S. Choudhury, P. Basu, M. Baker, S. Baker (Kolkata, India)

1:45pm-3:15pm: Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study

J. Hui, S. Fox, W. Neeson, P. Bhargava, E. Pappert, D. Blum, B. Navia (Los Angeles, CA, USA)

1:45pm-3:15pm: MRI cortical layer study in patients with Parkinson’s disease in Uzbekistan

A. Umarov, D. Tolibov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Multiple System Atrophy – perspectives in diagnosis?

P. Alster, D. Koziorowski, L. Królicki, A. Friedman (Warsaw, Poland)

1:45pm-3:15pm: Multiple system atrophy with predominant striato-nigral degeneration (MSA-P) and TDP-43 pathology: an unusual pathologic variant of MSA

L. Nwabuobi, D. Tomishon, N. Shneider, S. Fahn, J. Vonsattel, E. Cortes (New York, NY, USA)

1:45pm-3:15pm: Multiple System Atrophy: phenotypic spectrum approach coupled with brain FDG PET

A. Eusebio, E. Guedj, JP. Azulay, M. Renaud, M. Boucekine, S. Grimaldi (Marseille, France)

1:45pm-3:15pm: Neuroanatomical and clinical predictors of pain in patients with early de novo Parkinson’s disease

. Cousins, H. Wilson, T. Yousaf, S. Caminiti, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist

A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato, Italy)

1:45pm-3:15pm: Neuromelamin-MRI in patients with Pure Autonomic Failure

O. Roman, P. Trujillo-Diaz, K. Hay, I. Biaggioni, C. Shibao, D. Claassen (Nashville, TN, USA)

1:45pm-3:15pm: Neuromodulatory potentials of revasterol and Carpogon capitatus Roxb on the rat brain: Novel approach for Parkinson’s diseases

DS. Singh, MS. Singh, PK. Kumar, YK. Gupta (Allahabad, India)

1:45pm-3:15pm: Neuropathy in patients treated with LCIG in the Czech and the Slovak Republic

P. Havránková, J. Klempíř, J. Roth, E. Růžička, M. Baláž, M. Bareš, I. Rektorová, M. Kaiserová, P. Kaňovský, M. Minár, K. Gmitterová, P. Valkovič, M. škorvánek, V. Haň, L. Skička, J. Necpál, M. Grófik, E. Kurča, R. Jech (Praha, Czech Republic)

1:45pm-3:15pm: Neuroprotective effect of crocus sativus in lead-induced dopaminergic neurotoxicity in Meriones shawi: A possible link with Parkinson’s disease

L. Tamegart, A. Abbaoui, R. Makbal, M. Zroudi, M. Bouyatas, B. Bouizgarne, H. Gamrani (Marrakesh, Morocco)

1:45pm-3:15pm: Neuroprotective effect of Lemon oil on 6-OHDA-Induced Apoptosis in PC12 Cells through the ROS-NO Pathway

V. Kumar (Allahabad, India)

1:45pm-3:15pm: Neuroprotective effect of Yerba mate (Ilex paraguariensis) in a Drosophila model of Parkinson ’s disease

P. Ballestero, A. Bernardi, H. Hauche Pedernera, O. Gershanik, N. Muraro, J. Ferrario (Capital Federal, Argentina)

1:45pm-3:15pm: NEUROPSYCHIATRIC SYMPTOMS IN EARLY TO ADVANCED PATIENTS WITH THE RICHARDSON’S SYNDROME VARIANT OF PROGRESIVE SUPRANUCLEAR PALSY

A. Horta-Barba, J. Pagonabarraga, S. Martinez-Horta, B. Pascual-Sedano, J. Marin-Lahoz, J. Perez-Perez, I. Aracil-Bolanos, H. Bejr-Kasem, A. Campolongo, C. Izquierdo, F. Sampedro, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Nigral Iron Load as Diagnostic Parameter in Parkinson’s Disease

S. Franthal, L. Pirpamer, N. Homayoon, M. Koegl, P. Katschnig-Winter, K. Wenzel, C. Langkammer, S. Ropele, F. Fazekas, R. Schmidt, P. Schwingenschuh (Graz, Austria)

1:45pm-3:15pm: No difference in balance and gait parameters of the patients with akinetic-rigid and tremor-dominant Parkinson’s disease

AC. Kalkan, T. Kahraman, BO. Ugut, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Nocturnal stridor in multiple system atrophy: video-polysomnography and clinical features

H. Ryu, J. Paek, S. You, M. Kim, Y. Kim, J. Kim, K. Kim, S. Lee, S. Chung (Daegu, Republic of Korea)

1:45pm-3:15pm: Non-motor symptoms and risk of functional dependency in early Parkinson’s disease

R. Kim, D. Yoo, JH. Im, HJ. Kim, B. Jeon (Seoul, Republic of Korea)

1:45pm-3:15pm: Non-motor symptoms contribute to the caregiver burden in Progressive Supranuclear Palsy

ZC. Chen, YM. Liu (Jinan, China)

1:45pm-3:15pm: Nrf2 pathway in patients with Parkinson’s disease

T. Schirinzi, S. Petrillo, G. Di Lazzaro, N. Mercuri, E. Bertini, F. Piemonte, A. Pisani (Rome, Italy)

1:45pm-3:15pm: Nutritional status in patients with Parkinson’s disease and its relationship with the motor phenotype.

R. Cruz, J. Balderas, C. Navarro, L. Zuazua, M. Rodriguez, A. Cervantes (Mexico City, Mexico)

1:45pm-3:15pm: Ocular Motor Dysfunction as the Predictable Milestone of Life Prognosis in Progressive Supranuclear Palsy

T. Ishihara, T. Oeda, S. Tomita, A. Umemura, M. Kohsaka, K. Park, M. Tahara, K. Yamamoto, H. Sawada (Kyoto, Japan)

1:45pm-3:15pm: Osteopathic Manipulative Medicine to Improve Balance and Quality of Life in Parkinson Disease

S. Yao, J. Docherty, J. Mancini, A. Leder, J. Difrancisco-Donoghue (Old Westbury, NY, USA)

1:45pm-3:15pm: Pain assessment and pain management study in patients with Parkinson’s disease in Uzbekistan

A. Umarov, D. Tolibov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Pain in patients with multiple system atrophy: a pain-related evoked potential study

M. Takeda, F. Okada, H. Tachibana, S. Kasama, H. Yoshikawa (Nishinomiya, Japan)

1:45pm-3:15pm: Parkinson Disease Clinical Subtypes Predict Dementia and Mortality Risk

P. Myers, M. Campbell, A. Weigand, N. Cairns, J. Jackson, C. Lessov-Schlaggar, J. Perlmutter (St. Louis, MO, USA)

1:45pm-3:15pm: PARKINSON DISEASE HAMPERS PARTICIPATION IN THE CIVIC RESPONSIBILITY OF VOTING: a study of barriers to expression of a fundamental human right

O. Oguntunde, O. Ojo, O. Agabi, M. Rizig, N. Okubadejo (Lagos, Nigeria)

1:45pm-3:15pm: Parkinson’s Disease Presentation in Calabar, Nigeria

S. Oparah, U. Williams, J. Mwankon (Calabar, Nigeria)

1:45pm-3:15pm: Parkinson’s disease-associated mutations of PLA2G6 alters the membrane dynamics and α-synuclein stability

ａ. Mori, T. Hatano, T. Inoshita, K. Shiba-Fukushima, T. Koinuma, C. Yamashita, A. Okuzumi, Y. Imai, ｎ. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Parkinson’s disease and melanoma: a serie of 33 patients

J. Doridam, M. Nader, A. Melin, MF. Avril, E. Maubec, B. Degos (Paris, France)

1:45pm-3:15pm: Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study

J. Ihle, F. Artaud, S. Bekadar, G. Magnone, H. Bertrand, S. Sambin, LL. Mariani, C. Scherzer, A. Elbaz, JC. Cornol (Paris, France)

1:45pm-3:15pm: Parkinsonian syndrome associated to C9orf72 expansion

S. Novo Ponte, E. Gamo González, P. Sánchez Alonso (Majadahonda, Spain)

1:45pm-3:15pm: Parkinsonism and rapidly progressive dementia secondary to free-living ameba

M. Rubio Hernandez, I. Rodriguez Leyva, M. Tello Zavala, A. Ortiz Alvarez, C. Gallegos Rios (San Luis Potosi, Mexico)

1:45pm-3:15pm: Parkinsonism in HIV positive persons in South Africa

FH. Amod (Durban, South Africa)

1:45pm-3:15pm: Patient-Centered Outcomes of Deep Brain Stimulation in Parkinson’s Disease

R. Moraes, J. Freitas, R. Ferreira, P. Pereira, P. Terzian, F. Godinho, M. Rocha (Sao Paulo, Brazil)

1:45pm-3:15pm: Patients Experiencing Motor Fluctuations With Parkinson’s Disease (PD): Participant Characteristics in the Accordance Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa

P. Lewitt, R. Gendreau, J. Meckler, A. Hotovely-Salomon, N. Navon (West Bloomfield, MI, USA)

1:45pm-3:15pm: Pattern and Presentation of Parkinson Disease in two Teaching Hospitals in Enugu, South East Nigeria

B. Ezeala-Adikaibe (Enugu, Nigeria)

1:45pm-3:15pm: Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson’s disease is safe and may be advantageous

F. Baig, L. Mooney, M. Selikhova, M. Rolinski, K. Szewczyk-Krolikowski, N. Collin, A. Whone (Bristol, United Kingdom)

1:45pm-3:15pm: Peripheral Blood Mononuclear Cells (PBMCs) are Useful Biomarkers of Mitochondrial Dysfunction in Parkinson Disease Patients with Pathogenic Parkin and LRRK2 Mutations

P. Campbell, J. Harvey, A. Costantini, H. Morris, A. Schapira (London, United Kingdom)

1:45pm-3:15pm: Pharmacokinetics of ABBV-951 Following 24-Hour Continuous Subcutaneous Infusion to Arm, Abdomen and Thigh

M. Rosebraugh, P. Kym, W. Liu, M. Facheris, J. Benesh (North Chicago, IL, USA)

1:45pm-3:15pm: Pharmacokinetics of Accordion Pill™ Carbidopa/Levodopa Following Multiple Doses in Patients With Parkinson’s Disease

C. Olanow, F. Stocchi, M. Leinonen, N. Navon, J. Meckler, R. Gendreau (Sarasota, FL, USA)

1:45pm-3:15pm: Phenotypic spectrum of Progressive Supranuclear Palsy in a Tunisian cohort

A. Nasri, A. Neji, I. Kacem, T. Lansari, S. Mrabet, A. Gargouri, M. Ben Djebara, R. Gouider (Tunis, Tunisia)

1:45pm-3:15pm: Plasma-based circulating long non-coding RNA AS-Uch1 as a novel diagnostic biomarker for Parkinson’s disease

Y. Fan, Z. Xue (Wuhan, China)

1:45pm-3:15pm: Population Exposure-Response Modeling of the Effects of Apomorphine Sublingual Film on QTc in Patients With Parkinson’s Disease and “OFF” Episodes

F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

1:45pm-3:15pm: Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes

F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

1:45pm-3:15pm: Posterior cortical atrophy (PCA) attributable to corticobasal degeneration

H. Sienkiewicz-Jarosz, E. Bucior (Warsaw, Poland)

1:45pm-3:15pm: Postural alterations in patients with Progressive Supranuclear Palsy

C. Palmisano, M. Todisco, V. Maltese, R. Cilia, N. Pozzi, A. Canessa, M. Canesi, J. Volkmann, C. Frigo, G. Pezzoli, I. Isaias (Würzburg, Germany)

1:45pm-3:15pm: Postural instability secondary to hypoxic injury to the bilateral globus pallidi

D. Shpiner, J. Margolesky, H. Moore (Miami, FL, USA)

1:45pm-3:15pm: Pramipexole regulates the depressive-like symptom through dopamine D3 not dopamine D2 receptor in a mouse model of Parkinson’s disease

SZ. Wei, F. Wang, CF. Liu (Suzhou, China)

1:45pm-3:15pm: Predicting domain specific cognitive impairment in Parkinson’s disease

P. Zarifkar, J. Kim, C. La, P. Borghammer, K. Poston (Palo Alto, CA, USA)

1:45pm-3:15pm: Predictors of Retention for Carbidopa/Levodopa Intestinal Gel in Parkinson Disease

A. Nagy, T. Davis, T. Hassell, P. Hedera, D. Isaacs, H. Koons, F. Phibbs, S. Afrow, J. Fang (Nashville, TN, USA)

1:45pm-3:15pm: Preferred place of death (PPOD) in PD, PSP and MSA

C. Morris, R. Walker, M. Lee, J. Adamson (Newcastle, United Kingdom)

1:45pm-3:15pm: Premature State of Oligodendrocytes Potentially Provides Critical Period for Extracellular Pathological α-Synuclein to Invade Oligodendrocyte Lineage Cells

S. Kaji, T. Maki, T. Ayaki, R. Takahashi (Kyoto, Japan)

1:45pm-3:15pm: Preparing enhanced arm swing facilitates gait initiation in Parkinson’s disease: a combined EEG-EMG-IMU study

J. Weersink, N. Maurits, B. de Jong (Groningen, Netherlands)

1:45pm-3:15pm: Prevalence and predisposing factors of Parkinson disease: A barangay community-based study in Quezon, Philippines

MC. Rosales, DJ. Robles, RCN. Rodriguez, NB. Romana, JM. Rosales, G. Salazar, R. Rosales (Manila, Philippines)

1:45pm-3:15pm: Prevalence of advanced Parkinson’s disease in Thai patients with Parkinson’s disease using the Consensus on the Definition of Advance Parkinson’s disease (CEPA Study): A single-center study

J. Srikajon, P. Srivanitchapoom, Y. Pitakpatapee, A. Pisarnpong, T. Sangpeamsook, A. Suengtaworn (Bangkok, Thailand)

1:45pm-3:15pm: Prevalence of Parkinson’s disease and parkinsonism in Kyrgyzstan

C. Shambetova (Bishkek, Kyrgyzstan)

1:45pm-3:15pm: PRKN Positive Parkinson’s Disease Masked as Dopa-Responsive Dystonia

S. Chiu, A. Elkouzi, L. Almeida (Gainesville, FL, USA)

1:45pm-3:15pm: Progressive Parkinsonism and Cognitive Changes: A Rare Presentation of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)

M. Khyat-Khoei, J. Randhawa, E. Furr-Stimming, R. Samudralwar, S. Chandra (Houston, TX, USA)

1:45pm-3:15pm: Protective effects of β-Nicotinamide Adenine Dinucleotide against motor deficits and dopaminergic neuronal damage in a Parkinson’s disease mouse model

C. Shan, YL. Gong, QQ. Zhuang, YF. Hou, SM. Wang, ST. Li, JM. Liu (Shanghai, China)

1:45pm-3:15pm: PSP-like syndrome after aortic in adults (Mokri syndrome)

S. Tisel, J. Ahlskog, J. Matsumoto, J. Duffy, K. Josephs (Minneapolis, MN, USA)

1:45pm-3:15pm: Quantifying eye and gait abnormalities in Parkinson’s patients after Deep brain stimulation

Z. Su, M. Brzezick, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)

1:45pm-3:15pm: Quantitative Assessment of Saccadic Eye Movements in Progressive Supranuclear Palsy and Idiopathic Parkinson’s Disease

C. Fearon, Y. Llamas-Osorio, L. Williams, A. Laffan, P. Moloney, R. Field, R. Reilly, T. Lynch (Dublin, Ireland)

1:45pm-3:15pm: Quantitative straight and circular walking parameters for detecting ON and OFF medication states in early PD

MF. Corrà, N. Vila-Chã, J. Damasio, S. Duarte, A. Sardoreira-Bràs, P. Salgado, M. Calejo, C. Hansen, H. Minh Pham, R. Magalhães, M. Correia, W. Maetzler, L. Maia (Porto, Portugal)

1:45pm-3:15pm: Rapid Picture Naming in Parkinson’s Disease Using the Mobile Universal Lexicon Evaluation System (MULES) Test

J. Conway, C. Gonzalez, S. Fallon, J. Martone, L. Hasanaj, A. Lepor, L. Serrano, J. Rucker, S. Galetta, S. Frucht, L. Balcer (New York, NY, USA)

1:45pm-3:15pm: Rare manifestation of CNS Lupus: Parkinsonism

C. Wantaneeyawong, K. Kumchana (Chiang Mai, Thailand)

1:45pm-3:15pm: Real-life gait performance as a marker for motor fluctuations: the Parkinson@home Validation study

L. Evers, J. Raykov, R. Badawy, K. Claes, M. Meinders, J. Krijthe, T. Heskes, M. Little, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Relationship between functional exercise capacity and balance in patients with idiopathic Parkinson’s disease

BO. Ugut, T. Kahraman, AC. Kalkan, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Relationship between intestinal bacteria, bacterial metabolites and residual pesticides in Parkinson’s disease

M. Hirayama, T. Hamaguchi, M. Ito, T. Ishida, M. Kuki, T. Maeda, K. Kashihara, Y. Tsuboi, K. Ohno (Hukuoka, Japan)

1:45pm-3:15pm: REM sleep behavior disorder and REM sleep without atonia is a progression marker in Parkinson’s disease: a report from the DeNoPa cohort

F. Sixel-Döring, L. Zimansky, ML. Muntean, B. Mollenhauer, C. Trenkwalder (Kassel, Germany)

1:45pm-3:15pm: Repetitive transcranial magnetic stimulation can improve anxiety in Parkinson’s disease: a randomized, double-blind and controlled trial

A. Makkos-Weisz, N. Kovács, P. Endre, M. Kovács, D. Pintér (Pécs, Hungary)

1:45pm-3:15pm: Resting-state EEG functional connectivity in Parkinson’s disease

R. Shoorangiz, E. Peterson, R. Jones, L. Livingston, I. Kirk, L. Tippett, M. Livingstone, T. Anderson, J. Dalrymple-Alford (Christchurch, New Zealand)

1:45pm-3:15pm: Retinal thickness and microvascular pattern in early Parkinson’s disease.

C. Rascunà, C. Terravecchia, A. Russo, G. Mostile, CE. Cicero, A. Luca, N. Castellino, A. Longo, T. Avitabile, M. Reibaldi, M. Zappia, A. Nicoletti (Catania, Italy)

1:45pm-3:15pm: Risk of Parkinson’s in idiopathic anosmia

R. Rees, S. Gane, C. Philpott, A. Noyce, A. Schrag (Norwich, United Kingdom)

1:45pm-3:15pm: Role of APOE ε4 status and Sex on Somatosensory Integration and Dual-Task Cost in Parkinson’s disease

D. Martini, R. Morris, G. Mcbarron, T. Madhyastha, T. Grabowski, SC. Hu, C. Zabetian, A. Hiller, K. Chung, J. Quinn, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Role of microRNA-153 and -223 in Parkinson disease

M. Cressatti, W. Song, L. Jawura, J. Galindez, O. Canie, A. Velly, M. Gornitsky, H. Schipper (Montreal, QC, Canada)

1:45pm-3:15pm: Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson’s disease : a large single-center study

A-S. Blaise, G. Baille, N. Carrière, D. Devos, K. Dujardin, G. Grolez, A. Kreisler, M. Kyheng, C. Moreau, E. Mutez, D. Seguy, L. Defebvre (Lille, France)

1:45pm-3:15pm: Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis

W. Ondo, A. Ellenbogen, S. Isaacson, A. Espay, C. Singer, P. Bhargava, M. Worden, D. Blum, B. Navia (Houston, TX, USA)

1:45pm-3:15pm: Safety and Tolerability of opicapone in Parkinson’s disease

M. Campins Romeu, M. Losada López, I. Sastre Bataller, MJ. Pérez García, I. Martínez Torres (Valencia, Spain)

1:45pm-3:15pm: Scene Induced emotion processing in Parkinson’s disease: BOLD-fMRI study

S. Boujraf, M. Benzagmout, B. Alami, H. Amadou, H. El Hamdaoui, A. Bennani, M. Jaafari, I. Rammouz, M. Maaroufi, D. Boussaoud (Fez, Morocco)

1:45pm-3:15pm: Sensitivity of magnetic resonance imaging findings in the diagnosis of progressive supranuclear palsy

L. Marques, V. Silva, J. Araújo, S. Varanda, G. Carneiro, M. Rodrigues (Braga, Portugal)

1:45pm-3:15pm: Serological analysis of circulating Alpha Synuclein protein levels by Surface Plasmon Resonance (SPR) In Parkinson’s disease

A. Singh, T. Bajaj, A. Dey, S. Dey (New Delhi, India)

1:45pm-3:15pm: Serum mucosal chemokine levels in patients with Parkinson disease.

S. Haji, W. Sako, N. Murakami, Y. Osaki, Y. Izumi (Tokushima, Japan)

1:45pm-3:15pm: Serum non-mercaptalbumin as a potential biomarker in Parkinson’s disease and related disorders

S. Ueno, T. Hatano, A. Okuzumi, S. Saiki, Y. Oji, A. Mori, T. Koinuma, M. Fujimaki, H. Takeshige-Amano, K. Yasukawa, Y. Yatomi, H. Ikeda, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Serum uric acid level as a biomarker in sporadic and familial (p.A53T alpha synuclein carriers) Parkinson’s disease: Longitudinal data from the PPMI study

C. Koros, AM. Simitsi, M. Stamelou, D. Papadimitriou, A. Bougea, I. Pachi, N. Papagiannakis, A. Prentakis, E. Angelopoulou, R. Antonellou, M. Bozi, X. Geronicola Trapali, L. Stefanis (Athens, Greece)

1:45pm-3:15pm: Serum uric acid levels and cognitive function in Parkinson’s disease

J. Difrancisco-Donoghue, W. Werner, B. Krishnamachari, K. Arabian, E. Thomas, D. Granger, R. Gallagher (Irvine, CA, USA)

1:45pm-3:15pm: Sexual Needs & function assessment of patients with Parkinson’s disease in the tertiary movement disorder’s center

S. Peleg Nesher, Y. Manor, A. Rosenberg, S. Naor, T. Taichman, A. Ezra, D. Roque, J. Shurer, D. Drazheva, N. Browner, K. Robertson, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Skin in the game: Small fiber neuropathy in Parkinson’s disease and atypical parkinsonisms.

R. Infante, G. Rizzo, A. Incensi, C. Scaglione, S. Capellari, V. Donadio, R. Liguori (Bologna, Italy)

1:45pm-3:15pm: Special features of parkinsonism with congenital anomalies of cerebral vessels

AS. Norboboev, FAY. Odinaev, GUL. Rakhmatullaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Spectrum of parkinsonian phenotypes associated with GCH1 mutation.

D. Al-Shorafat, A. Shetty, D. Munoz, A. Fasano, A. Lang (Toronto, ON, Canada)

1:45pm-3:15pm: Speculation on the timing of iron deposition in the putamen of patients with multiple system atrophy: multimodal MRI study

MJ. Lee, JH. Lee (Yangsan-Si, Republic of Korea)

1:45pm-3:15pm: Speech and language changes in cognitive impairment subtypes in patients with Parkinson´s disease

A. Kušnírová, Z. Košutzká, M. Hajdúk, M. Králová, M. Pápayová, M. Egryová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)

1:45pm-3:15pm: Spin turns and step turns in advanced Parkinson’s disease: a new clinical gait sign?

O. Gavriliuc, S. Paschen, A. Andrusca, C. Schlenstedt, G. Deuschl (Chisinau, Republic of Moldova)

1:45pm-3:15pm: Steering the Volume of Tissue Activated with Directional Deep Brain Stimulation Lead in the Globus Pallidus internus

S. Zhang, E. Pereira, N. Pouratian, A. Kent, B. Cheeran, L. Venkatesan, A. Schnitzler (Plano, TX, USA)

1:45pm-3:15pm: Stereopsis as a Visual Biomarker for Parkinson’s Disease

T. Sang, J. Fatehi, E. Mostofi, B. Zheng, F. Ba (Edmonton, AB, Canada)

1:45pm-3:15pm: Stimulation Frequency and Active Contact Location Influence Speech Problems in Parkinson’s Disease Patients with Bilateral Subthalamic Deep Brain Stimulation

O. Phokaewvarangkul, K. Boonpang, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: STN-DBS programing for dyskinesia: a case report

L. Li, Y. Zhang (Beijing, China)

1:45pm-3:15pm: Striatal dopaminergic regulation of micrographia in parkinsonism

M. Eklund, J. Joutsa, S. Nuuttila, E. Mäkinen, E. Jaakkola, T. Noponen, T. Ihalainen, M. Koivisto, S. Teperi, F. Scheperjans, V. Kaasinen (Turku, Finland)

1:45pm-3:15pm: Structural connectivity changes in prodromal Parkinson’s disease patients: a multimodal MRI study

V. Suarez Contreras, G. Pagano, J. Fernandez Bonfante, H. Wilson, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Study of cardiac sympathetic denervation by 18F-FDOPA PET-CT Imaging in early Parkinson disease (EPD) and Atypical parkinsonian syndromes (APS)

K C. Chudasama, VG. Goyal, C P. Patel, MV. Srivastava, MBS. Singh, MT. Tripathi, VY. Y, AR. Roy (Delhi, India)

1:45pm-3:15pm: Successful treatment of Parkinson’s disease-related impulse control disorder with bilateral STN DBS

T. Stiep, D. Spengler Shpiner, C. Luca (Miami, FL, USA)

1:45pm-3:15pm: Swallowing assessment in Parkinson’s Disease using Dynamic Magnetic Resonance Imaging (dMRI)

SG. Gudwani, PU. Upadhyay, KS. Sharma, RS. Sagar, SSK. Kumaran, RKD. Dhamija (New Delhi, India)

1:45pm-3:15pm: Synaptic dysfuncion in a Drosophila model of PARK14

T. Hatano, A. Mori, T. Inoshita, K. Fukushima-Shiba, T. Koinuma, C. Yamashita, Y. Imai, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Synaptic function in Parkinson’s disease associated with GBA mutations

T. Eid, R. Bandopadhyay, T. Lashley, J. Hardy, J. Holton, T. Warner, P. Francis (London, United Kingdom)

1:45pm-3:15pm: Tau and amyloid-beta inclusions are present in pancreatic beta-cells of patients with synucleinopathies

I. Martinez-Valbuena, R. Valenti-Azcarate, J. Sanchez, I. Marcilla Garcia, I. Amat-Villegas, MT. Tuñon-Alvarez, MR. Luquin Piudo (Pamplona, Spain)

1:45pm-3:15pm: The association between frailty and Parkinson’s in the ReSPOnD trial

N. Smith, D. Gaunt, A. Whone, Y. Ben-Shlomo, E. Henderson (Bath, United Kingdom)

1:45pm-3:15pm: The carotid ultrasonography revealed vagus nerve atrophy of the patients with parkinsonism

S. Abe, T. Hirato, H. Saiki (Osaka, Japan)

1:45pm-3:15pm: The Chinese Parkinson’s disease Registry scheme

XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Q. Xu, Y. Tian, LJ. Fang, ZQ. Wang, QY. Sun, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: The congruence of asymmetry between motor symptoms and retinal thickness in Parkinson’s disease

W. Suh, JY. Hong, SY. Kang (Wonju, Republic of Korea)

1:45pm-3:15pm: The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson’s disease

I. Rektor, B. Vesely, N. Bohnen, E. Koritakova, E. Kurca, P. Valkovic (Brno, Czech Republic)

1:45pm-3:15pm: The Dutch Parkinson and Microbiome Study (DUPARM): Gut Microbiome Composition of Treatment-Naïve De Novo Parkinson’s Disease Patients

J. Boertien, S. Vander Zee, T. van Laar (Groningen, Netherlands)

1:45pm-3:15pm: The effect of active contact localization on motor symptoms in deep brain stimulation of the subthalamic nucleus for Parkinson’s disease

T. Ten Brinke, V. Odekerken, P. Schuurman, R. de Bie (Amsterdam, Netherlands)

1:45pm-3:15pm: The effect of baseline cognitive status of Parkinson’s disease on the outcome after deep brain stimulation surgery

KW. Park, NR. Choi, SY. Jo, MS. Kim, NE. Han, SR. Jeon, SJ. Chung (Seoul, Republic of Korea)

1:45pm-3:15pm: The effect of coexistent neurodegenerative disorders on the clinical features of idiopathic normal pressure hydrocephalus

A. Hattori, T. Tsunemi, N. Hattori (Bunkyo-Ku, Japan)

1:45pm-3:15pm: The Effects of Computer Based Cognitive Rehabilitation on working memory in patients with Parkinson’s disease: A Systematic Review

A. Loekkegaard, M. Niemeijer, K. Svaerke (Copenhagen, Denmark)

1:45pm-3:15pm: The effects of obstacle size and timing on prefrontal cortex activation in patients with Parkinson’s disease

I. Maidan, T. Sharon, I. Kurz, H. Bernad-Elazari, S. Shustak, I. Galperin, N. Giladi, A. Mirelman, J. Hausdorff (Tel Aviv, Israel)

1:45pm-3:15pm: The effects of timed exposure to bright light in improving the gait patterns of patients with Parkinson’s disease – A pilot study

L. Alibiglou, T. Ruopp (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: The effects of zonisamide on motor and non-motor symptoms in patients with Parkinson’s disease: a 3-month open-label study

K. Suzuki, H. Fujita, T. Matsubara, T. Kadowaki, K. Funakoshi, Y. Watanabe, T. Shiina, H. Sakuramoto, M. Hamaguchi, K. Hirata (Tochigi, Japan)

1:45pm-3:15pm: The Efficacy and Safety of Subcutaneous Apomorphine in Patients with Parkinson’s Disease: A Meta-Analysis Randomized Controlled Trials

M. Azharuddin, M. Adil, P. Ghosh, M. Sharma (New Delhi, India)

1:45pm-3:15pm: THE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON’S DISEASE

N. Djebli (Mostaganem, Algeria)

1:45pm-3:15pm: The frequency and impact of mutations in the GBA gene and APOε4 polymorphisms on the clinical features of Dementia with Lewy Bodies among Ashkenazi Jews

T. Shiner, A. Mirelman, Y. Rozenblum, G. Kave', M. Gana Weisz, A. Bar-Shira, A. Thaler, R. Shahar, T. Gurevich, A. Orr-Urtreger, N. Giladi, N. Bregman (Tel Aviv, Israel)

1:45pm-3:15pm: The impact of HIV on the severity and course of Parkinson’s disease: a clinical case

A. Kudrevatykh, E. Gracheva, I. Miliukhina (St. Petersburg, Russian Federation)

1:45pm-3:15pm: The impact of medication and deep brain stimulation on visuo-motor coordination in Parkinson’s disease

J. Daneault, A. Sadikot, B. Carignan, M. Panisset, C. Duval (Newark, NJ, USA)

1:45pm-3:15pm: The Impact of Progressive Supranuclear Palsy (PSP) Disease Severity on Healthcare Resource Utilization (HCRU)

T. Xie, X. Ye, J. de Courcy, J. Mellor, J. Zamudio, L. Chiodo, Y. Bao (Mettawa, IL, USA)

1:45pm-3:15pm: The long-term effect of continuous apomorphine treatment on camptocormia in Parkinson´s disease: a 24-months longitudinal open, prospective follow-up study

K. Mensikova, M. Kaiserova, M. Vastik, M. Nevrly, S. Kurcova, P. Kanovsky (Olomouc, Czech Republic)

1:45pm-3:15pm: The management of Parkinson’s Disease during pregnancy: literature review, case series and multi-disciplinary input

C. Young, R. Phillips, L. Ebenezer, R. Zutt, C. Mitchell, K. Peall (Cardiff, United Kingdom)

1:45pm-3:15pm: The Oral Metagenome and Metatranscriptome of Early Stage Parkinson’s Disease and their Relationship with Clinical and Functional Outcome Measures of Motor and Nonmotor Function

D. Mihaila, J. Donegan, M. Vidal, D. Larocca, R. Ericson, S. Barns, C. Neville, R. Uhlig, F. Middleton (Syracuse, NY, USA)

1:45pm-3:15pm: The Power of Normal Saline in Reducing Skin Nodules in Apomorphine

F. Leen, A. Evans, T. Canento, M. Ghaly, C. Wools, B. Cruse, M. Beckley (Melbourne, Australia)

1:45pm-3:15pm: The prevalence of ICBs in patients treated with apomorphine infusion: a retrospective analysis

P. Barbosa, A. Lees, A. Djamshidian, T. Warner (Innsbruck, Austria)

1:45pm-3:15pm: The Progressive Supranuclear Palsy Functional Disability Scale: Sensitivity to change

I. Piot, K. Schweyer, G. Respondek, M. Grimm, M. Stamelou, P. Sckopke, T. Schenk, C. Goetz, G. Stebbins, G. Höglinger (Munich, Germany)

1:45pm-3:15pm: The relationship between constipation and alteration of gut microbiota in patients with Parkinson’s disease

BI. Zao An, M. Ye (Nanjing, China)

1:45pm-3:15pm: The role of Dopamine in Preparatory Inhibition: What can we learn from Parkinson’s disease?

E. Wilhelm, C. Quoilin, G. Derosiere, A. Jeanjean, J. Duqué (Brussels, Belgium)

1:45pm-3:15pm: The role of mitochondria in modifying penetrance of Parkin gene variants

M. Castelo, J. Trinh, A. Zanon, J. Rainer, P. Bauer, K. Kandaswamy, M. Werber, A. Rolfs, A. Grunewald, M. Borsche, K. Lohmann, C. Klein, P. Pramstaller, I. Pichler, A. Hicks (Bolzano, Italy)

1:45pm-3:15pm: The role of Parkinson’s disease-associated RHOT1/Miro1 variants in mitochondrial dysfunction and impaired cellular quality control

A. Chemla, C. Berenguer-Escuder, F. Massart, P. Seibler, C. Klein, D. Grossmann, A. Grünewald, R. Krüger (Belvaux, Luxembourg)

1:45pm-3:15pm: The role of the gut microbial dysbiosis and serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease

I. Miliukhina, E. Ermolenko, E. Gracheva, A. Istomina, M. Kotyleva, E. Agapova, A. Suvorov (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: The STN Sweet Spot for Tremor Control in Parkinson’s Disease

T. Stiep, A. Diaz, I. Cajigas, J. Jagid, C. Luca (Miami, FL, USA)

1:45pm-3:15pm: The SUNRISE-PD Study, a clinical trial of AXO-LENTI-PD: a CNS-directed gene therapy for the treatment of Parkinson’s Disease

G. Corcoran, P. Korner, J. Wright, Y. Mo, J. Benoit, K. Binley, J. Miskin, N. Tuckwell, D. Zamoryakhin, T. Foltynie, R. Barker, K. Mitrophanous, S. Palfi (New York, NY, USA)

1:45pm-3:15pm: The trace of substantia nigra hyperechogenicity: a clinical observation

A. Alonso-Canovas, JL. Sendon-Moreno, G. Garcia-Ribas, N. Monterde-Gonzalez, C. Jara-Laguna, JC. Martinez-Castrillo, J. Masjuan (Madrid, Spain)

1:45pm-3:15pm: The ultrasonographic assessment of vagus nerve atrophy comparison with autonomic dysfunction in Parkinson’s disease

T. Hirato, S. Abe, H. Saiki (Kita-Ku, Osaka, Japan)

1:45pm-3:15pm: The Use of Exergames in Neurorehabilitation in People with Parkinson’s Disease: Its Impact on Daily Life

B. Zeigelboim, H. Teive, M. Severiano, G. Dos Santos, M. da Rosa, M. José, R. Sampaio, J. Malisky (Curitiba, Brazil)

1:45pm-3:15pm: Therapeutic management of complicated Parkinson’s disease: clinical application of the Motor Fluctuation Indices

R. Bonomo, G. Mostile, A. Nicoletti, M. Zappia (Catania, Italy)

1:45pm-3:15pm: THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)

S. Shrewsbury, J. Campbell, M. Swardstrom, A. Lehn, K. Satterly, J. Hoekman (Seattle, WA, USA)

1:45pm-3:15pm: Three-year follow-up of a patient with a rare combination of taupathy (PSP) and synucleopathy (MSA)

D. Aygun (Samsun, Turkey)

1:45pm-3:15pm: Time-Frequency analysis of Gait-EEG signals for freezing of gait in a PD patient

J. Li, Y. Zhang (Beijing, China)

1:45pm-3:15pm: To compare early / late onset MSA from the PAN American MSA (PANMSA) database

M. Cesarini, E. Gatto, J. Etcheverry, G. da Prat, F. Peralta (Caba, Argentina)

1:45pm-3:15pm: Towards unobtrusive Parkinson’s disease detection via motor symptoms severity inference from multimodal smartphone-sensor data

D. Iakovakis, S. Hadjidimitriou, V. Charisis, K. Kyritsis, A. Papadopoulos, M. Stadtschnitzer, H. Jaeger, I. Dagklis, S. Bostantjopoulou, Z. Katsarou, L. Klingelhoefer, S. Mayer, R. Reichmann, D. Trivedi, A. Podlewska, A. Rizos, K. Chaudhuri, A. Delopoulos, L. Hadjileontiadis (Thessaloniki, Greece)

1:45pm-3:15pm: Transcranial ultrasound in atypical parkinsonism: how reliable is it in real clinical practice? A multi-centre comprehensive study

A. Alonso-Canovas, JI. Tembl-Ferrairo, I. Martinez Torres, JL. Lopez Sendon-Moreno, I. Parees-Moreno, E. Monreal-Laguillo, P. Perez-Torre, R. Toledano, G. Garcia-Ribas, J. Masjuan, JC. Martinez-Castrillo, U. Walter (Rostock, Germany)

1:45pm-3:15pm: Unraveling biological processes implicated in MSA and PD by transcriptomic analysis

A. Perez-Soriano, M. Arnal, D. Giraldo, M. Fernandez, T. Botta-Orfila, Y. Compta, R. Fernández-Santiago, M. Ezquerra, D. Tartaglia, MJ. Martí (Barcelona, Spain)

1:45pm-3:15pm: Using Quantitative Susceptibility Mapping to Predict Dementia in Parkinson’s Disease

G. Thomas, L. Leyland, J. Acosta-Cabronero, R. Weil (London, United Kingdom)

1:45pm-3:15pm: Utilising Magnetic Resonance Spectroscopy to investigate synucleinopathies

N. Khalil, E. Matar, S. Duffy, S. Lewis (Camperdown, Australia)

1:45pm-3:15pm: Utility of Eye Movement Abnormalities in Differentiating Neurodegenerative versus non-Neurodegenerative Parkinsonism

A. Margolius, D. Hengartner, O. Hogue, X. Garcia, S. Patel, A. Ahmed, H. Fernandez, XX. Yu (Bogota, Colombia)

1:45pm-3:15pm: Validation of the diagnostic criteria for progressive supranuclear palsy in pathologically confirmed patients

I. Aiba, Y. Saito, Y. Yokokawa, T. Katayama, M. Kenjo, R. Hashimoto, S. Sakakibara, M. Sato, H. Nakatsuji, A. Inukai, Y. Iwasaki, M. Mimuro, A. Akagi, M. Yoshida (Nagoya, Japan)

1:45pm-3:15pm: Validation of the Movement Disorder Society criteria for the diagnosis of 4R-tauopathies

G. Respondek, MJ. Grimm, I. Piot, T. Arzberger, Y. Compta, E. Englund, LW. Ferguson, E. Gelpi, A. Giese, S. Roeber, DJ. Irwin, WG. Meissner, C. Nilsson, A. Pantelyat, A. Rajput, JB. Rowe, JC. van Swieten, C. Troakes, GU. Höglinger (London, United Kingdom)

1:45pm-3:15pm: Validation of the PREDIGT Score for the Incidence Rate of Parkinson disease

J. Li, T. Mestre, J. Tomlinson, M. Frasier, E. Lang, B. Mollenhauer, T. Ramsay, D. Manuel, M. Schlossmacher (Goettingen, Germany)

1:45pm-3:15pm: Vascular Parkinsonism and Parkinson’s Disease: clinical differences concerning balance impairment

R. Jesus, R. Raimundo, C. Azoia, M. Mendes, V. Espirito-Santo, A. Almeida, I. Rego, AG. Velon (Vila Real, Portugal)

1:45pm-3:15pm: Vascular risk factors and depression in multiple system atrophy

LY. Zhang, B. Cao, QQ. Wei, RW. Ou, HF. Shang (Chengdu, China)

1:45pm-3:15pm: Vertebral pain and bone mineral density in women with Parkinson’s disease

I. Karaban, V. Povoroznyuk, M. Bystrytska, N. Karasevich, N. Grygorieva (Kyiv, Ukraine)

1:45pm-3:15pm: Vocal cords electromyography abnormalities in multiple system atrophy phenotypes: relevance for the pathophysiology of stridor

M. Todisco, E. Alfonsi, I. Isaias, R. Zangaglia, B. Minafra, M. Terzaghi, N. Pozzi, C. Pacchetti (Pavia, Italy)

1:45pm-3:15pm: Zonisamide ameliorates levodopa-induced dyskinesia via striatal cholinergic system in a rat model of Parkinson’s disease

S. Kaneko, S. Morise, R. Tohge, M. Oki, M. Nakamura, N. Takenouchi, H. Kusaka (Hirakata, Japan)

1:45pm-3:15pm: Сhange In The Body Composition Of Patients With Parkinsonism For 2 Years

D,A. Akramova, G. Rakhimbaeva, D. Bobomuratova (Tashkent, Uzbekistan)

« View all sessions from the 2019 International Congress.